WO2024087515A1 - 抗cd16a的抗体及其应用 - Google Patents

抗cd16a的抗体及其应用 Download PDF

Info

Publication number
WO2024087515A1
WO2024087515A1 PCT/CN2023/086262 CN2023086262W WO2024087515A1 WO 2024087515 A1 WO2024087515 A1 WO 2024087515A1 CN 2023086262 W CN2023086262 W CN 2023086262W WO 2024087515 A1 WO2024087515 A1 WO 2024087515A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cd16a
seq
antigen
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/086262
Other languages
English (en)
French (fr)
Inventor
成赢
曹国帅
武玉伟
李洋洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hefei TG ImmunoPharma Co Ltd
Original Assignee
Hefei TG ImmunoPharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hefei TG ImmunoPharma Co Ltd filed Critical Hefei TG ImmunoPharma Co Ltd
Priority to JP2025524844A priority Critical patent/JP2026512563A/ja
Priority to AU2023370296A priority patent/AU2023370296A1/en
Priority to KR1020257017243A priority patent/KR20250084976A/ko
Priority to IL320488A priority patent/IL320488A/en
Priority to EP23881112.9A priority patent/EP4596581A4/en
Publication of WO2024087515A1 publication Critical patent/WO2024087515A1/zh
Priority to US19/188,009 priority patent/US20250297012A1/en
Priority to MX2025004739A priority patent/MX2025004739A/es
Anticipated expiration legal-status Critical
Priority to ZA2025/03670A priority patent/ZA202503670B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the present invention relates to the field of biomedicine, and in particular to an anti-CD16A antibody and application thereof.
  • NK cells Natural killer cells
  • T cells Unlike T cells, NK cells do not express antigen-specific receptors. NK cells themselves have a broad spectrum of tumor-killing capabilities and also play an important role in enhancing antibody and T cell responses.
  • NK cell-based tumor immunotherapy takes various forms and uses different methods. A decrease in the number of NK cells or impaired function is associated with the progression of various types of cancer. "Cold tumors" are immunologically insensitive, with few or no MHC class I molecules expressed on their surface, so they are rarely recognized by T cells, but can be recognized and killed by NK cells. The introduction of this concept has enhanced the status of NK cells in anti-tumor immunotherapy.
  • the CD16 molecule is an important marker on the surface of NK cells, which can activate the immunoreceptor tyrosine-based activation motif (ITAM) of IgE NK cell receptor (Fc ⁇ RI ⁇ ) and CD3 ⁇ to produce ADCC. Therefore, the CD16 target is preferentially selected in bispecific antibodies based on NK cell redirection.
  • ITAM immunoreceptor tyrosine-based activation motif
  • the CD16 target is widely selected in bispecific antibodies based on NK cell redirection (McCall et al., 1999, Gleason et al., 2014).
  • AFM13 is a bispecific antibody targeting CD16A and CD30 molecules, which can promote NK cells to kill CD30+ non-Hodgkin lymphoma cells (Reusch et al., 2014, Pahl et al., 2018).
  • NKCEs trifunctional antibodies
  • NKCEs have stronger in vitro killing ability than clinical therapeutic monoclonal antibodies, and their in vivo stability and tumor control ability are excellent (Gauthier et al., 2019).
  • Human CD16 can be divided into CD16A and CD16B, of which CD16A is mainly expressed in NK cells.
  • CD16B is mainly produced by multinuclear granulocytes, and there are also soluble receptors in human serum.
  • CD16A has polymorphic differences at position 158.
  • CD16A 158V has a higher affinity with the antibody Fc domain than CD16A 158F .
  • CD16B also has polymorphic differences in the human population, namely CD16B NA1 , CD16B NA2 and CD16B SH .
  • previous CD16 antibodies (such as 3G8), they basically recognized CD16 rather than CD16A specifically. Therefore, in the design of bispecific antibodies or multispecific antibodies, antibodies that recognize CD16A need to be developed in order to specifically target NK cells.
  • NK cells themselves have a broad spectrum of tumor-killing capabilities and also play an important role in enhancing antibody and T cell responses.
  • CD16A protein is mainly expressed in NK cells, and the CD16 target is preferentially selected in bispecific antibodies based on NK cell redirection.
  • the inventors of the present application have successfully screened a mouse anti-CD16A monoclonal antibody, which has high binding activity to human or monkey CD16A protein.
  • the inventors humanized the constant region of the above monoclonal antibody and retained the CDR of the mouse anti-CD16A monoclonal antibody to obtain a chimeric antibody.
  • the framework region in the light chain variable region or the heavy chain variable region of the chimeric antibody was humanized to obtain a fully humanized anti-CD16A antibody.
  • the humanized antibody can not only specifically target and bind to human CD16A protein and monkey CD16A protein, but also has the characteristics of low immunogenicity, and can effectively treat and/or prevent CD16A-mediated related diseases, such as autoimmune diseases.
  • the bispecific binding molecules or multispecific binding molecules prepared using the anti-CD16A antibodies can also specifically target and bind to human CD16A protein and monkey CD16 protein, and generally, based on the specificity of the bispecific binding molecules or multispecific binding molecules, the bispecific binding molecules or multispecific binding molecules can target NK cells to other antigens, eliminate cells that produce such antigens through NK cell-mediated cell killing, and thus treat a variety of diseases, such as tumors.
  • the present invention proposes an antibody or antigen-binding fragment.
  • it comprises heavy chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NO: 1, 2 and 3 or amino acid sequences with at least 95% identity to SEQ ID NO: 1, 2 and 3; and/or light chain variable region CDR1, CDR2, CDR3 sequences as shown in SEQ ID NO: 4, 5 and 6 or amino acid sequences with at least 95% identity to 4, 5 and 6.
  • the antibody or antigen-binding fragment according to the embodiment of the present invention can bind to human or monkey CD16A protein and effectively treat or prevent CD16A-mediated related diseases.
  • the above-mentioned antibody or antigen-binding fragment may further include at least one of the following additional technical features:
  • the antibody or antigen-binding fragment comprises: at least one of a heavy chain FR region and a light chain FR region.
  • At least a portion of at least one of the heavy chain FR region and the light chain FR region is derived from a human antibody, a primate antibody, or a mouse antibody. At least one of an antibody or a mutant thereof.
  • the antibody or antigen-binding fragment comprises: at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences shown in SEQ ID NO: 7 to 10, respectively; or at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences shown in SEQ ID NO: 15 to 18, respectively.
  • the antibody or antigen-binding fragment comprises: at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences shown in SEQ ID NO: 11 to 14, respectively; or at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences shown in SEQ ID NO: 19 to 22, respectively.
  • the antibody or antigen-binding fragment comprises: at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences as shown in SEQ ID NO: 7 to 10, respectively; at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences as shown in SEQ ID NO: 11 to 14, respectively; or at least one of the heavy chain framework region HFR1, HFR2, HFR3 and HFR4 sequences as shown in SEQ ID NO: 15 to 18, respectively; at least one of the light chain framework region LFR1, LFR2, LFR3 and LFR4 sequences as shown in SEQ ID NO: 19 to 22, respectively.
  • the antibody or antigen-binding fragment includes: a heavy chain variable region as shown in SEQ ID NO: 23 or SEQ ID NO: 25; and/or a light chain variable region as shown in SEQ ID NO: 24 or SEQ ID NO: 26.
  • the antibody or antigen-binding fragment includes: 1) a heavy chain variable region as shown in SEQ ID NO:23, and a light chain variable region as shown in SEQ ID NO:24; or 2) a heavy chain variable region as shown in SEQ ID NO:25, and a light chain variable region as shown in SEQ ID NO:26.
  • the antibody or antigen-binding fragment contains at least one of a heavy chain constant region and a light chain constant region, and at least a portion of at least one of the heavy chain constant region and the light chain constant region is derived from at least one of a human antibody, a primate antibody and a murine antibody or a mutant thereof.
  • the light chain constant region and the heavy chain constant region are both derived from a murine IgG antibody or a mutant thereof or a human IgG antibody or a mutant thereof.
  • the light chain constant region and the heavy chain constant region are both derived from a murine IgG1 antibody or a mutant thereof or a human IgG1 antibody or a mutant thereof.
  • the antibody has a heavy chain constant region with an amino acid sequence as shown in SEQ ID NO: 27 or 29 and/or a light chain constant region with an amino acid sequence as shown in SEQ ID NO: 28 or 30.
  • the antibody or antigen-binding fragment has a heavy chain having an amino acid sequence shown in any one of SEQ ID NO: 31, 33 and 35, and a light chain having an amino acid sequence shown in any one of SEQ ID NO: 32, 34 and 36.
  • the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:31 and a light chain with an amino acid sequence shown in SEQ ID NO:32; the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:33 and a light chain with an amino acid sequence shown in SEQ ID NO:34; or the antibody or antigen-binding fragment has a heavy chain with an amino acid sequence shown in SEQ ID NO:35 and a light chain with an amino acid sequence shown in SEQ ID NO:36.
  • the antibody or antigen-binding fragment comprises a monoclonal antibody or a polyclonal antibody.
  • the monoclonal antibody includes at least one of Fv, single-chain antibody, Fab, single-domain antibody and minimum recognition unit.
  • the antibody or its antigen-binding fragment is capable of binding to the amino acid sequence shown in SEQ ID NO:37 and/or 38.
  • the present invention proposes a bispecific binding molecule.
  • it includes a first binding region, the first binding region comprises the antibody or antigen binding fragment described in the first aspect; and a second binding region, the second binding region has BCMA or B7H6 binding activity.
  • the bispecific binding molecule according to an embodiment of the present invention can bind to human or monkey CD16A protein and BCMA protein, or to human or monkey CD16A protein and B7H6 protein, and can be applied to scientific research, or effectively treat or prevent CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the binding activity of the second binding region is not particularly limited and may have other binding activities, as long as the bispecific antibody has the antibody or antigen-binding fragment described in the first aspect, and the antibody or antigen-binding fragment and the second binding region can both effectively function.
  • the antibodies or antigen-binding fragments described in the present application can also be used to prepare more specific antibodies, such as trispecific, tetraspecific, and pentaspecific. Based on the multispecificity of the antibody, the antibody or antigen-binding fragment of the present invention can target NK cells to other antigens and eliminate cells that produce such antigens through NK cell-mediated cell killing.
  • the above-mentioned bispecific binding molecule may further include at least one of the following additional technical features:
  • the bispecific binding molecule includes a symmetric bispecific binding molecule or an asymmetric bispecific binding molecule.
  • the bispecific binding molecule is an asymmetric bispecific binding molecule.
  • the antibody or antigen-binding fragment is an anti-CD16A single-chain antibody.
  • the second binding region comprises at least one of a full-length antibody, Fv, single-chain antibody, Fab, single-domain antibody and a minimum recognition unit having BCMA or B7H6 binding activity.
  • the second binding region comprises an anti-BCMA single-chain antibody or an anti-B7H6 single-chain antibody.
  • the anti-CD16A single-chain antibody comprises an anti-CD16A antibody light chain variable region and an anti-CD16A antibody heavy chain variable region
  • the anti-CD16A antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO: 23 or 25
  • the anti-CD16A antibody light chain variable region has the amino acid sequence shown in SEQ ID NO: 24 or 26.
  • the anti-CD16A single-chain antibody further includes a connecting peptide 1, wherein the N-terminus of the connecting peptide 1 is connected to the C-terminus of the heavy chain variable region of the anti-CD16A antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the light chain variable region of the anti-CD16A antibody; or the N-terminus of the connecting peptide 1 is connected to the C-terminus of the light chain variable region of the anti-CD16A antibody, and the C-terminus of the connecting peptide 1 is connected to the N-terminus of the heavy chain variable region of the anti-CD16A antibody.
  • the anti-BCMA single-chain antibody comprises an anti-BCMA antibody light chain variable region and an anti-BCMA antibody heavy chain variable region
  • the anti-BCMA antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO:59
  • the anti-BCMA antibody light chain variable region has the amino acid sequence shown in SEQ ID NO:60.
  • the anti-BCMA single-chain antibody further includes a connecting peptide 2, wherein the N-terminus of the connecting peptide 2 is connected to the C-terminus of the anti-BCMA antibody heavy chain variable region, and the C-terminus of the connecting peptide 2 is connected to the N-terminus of the anti-BCMA antibody light chain variable region; or the N-terminus of the connecting peptide 2 is connected to the C-terminus of the anti-BCMA antibody light chain variable region, and the C-terminus of the connecting peptide 2 is connected to the N-terminus of the anti-BCMA antibody heavy chain variable region.
  • the anti-B7H6 single-chain antibody comprises an anti-B7H6 antibody light chain variable region and an anti-B7H6 antibody heavy chain variable region
  • the anti-B7H6 antibody heavy chain variable region has the amino acid sequence shown in SEQ ID NO:61
  • the anti-B7H6 antibody light chain variable region has the amino acid sequence shown in SEQ ID NO:62.
  • the anti-B7H6 single-chain antibody further includes a connecting peptide 3, wherein the N-terminus of the connecting peptide 3 is connected to the C-terminus of the heavy chain variable region of the anti-B7H6 antibody, and the C-terminus of the connecting peptide 3 is connected to the N-terminus of the light chain variable region of the anti-B7H6 antibody; or the N-terminus of the connecting peptide 3 is connected to the C-terminus of the light chain variable region of the anti-B7H6 antibody, and the C-terminus of the connecting peptide 3 is connected to the N-terminus of the heavy chain variable region of the anti-B7H6 antibody.
  • At least one of the connecting peptide 1, the connecting peptide 2 and the connecting peptide 3 has an amino acid sequence (GGGGS)n, wherein n is an integer greater than or equal to 1, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • n is an integer greater than or equal to 1, preferably 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
  • conventional connecting peptides in the art can be used, such as conventional flexible amino acid fragments or rigid amino acid fragments.
  • At least one of the connecting peptide 1, connecting peptide 2 and connecting peptide 3 has the amino acid sequence shown in SEQ ID NO:44.
  • the anti-CD16A single-chain antibody has an amino acid sequence as shown in SEQ ID NO:41.
  • the anti-BCMA single-chain antibody has an amino acid sequence as shown in SEQ ID NO:42.
  • the anti-B7H6 single-chain antibody has an amino acid sequence as shown in SEQ ID NO:43.
  • the first antigen binding region further includes a first Fc peptide segment, and the N-terminus of the first Fc peptide segment is connected to the C-terminus of the antibody or antigen binding fragment.
  • the second antigen binding region further includes a second Fc peptide segment, and the N-terminus of the second Fc peptide segment is connected to the C-terminus of the anti-BCMA single-chain antibody or the anti-B7H6 single-chain antibody.
  • the first Fc peptide segment has the amino acid sequence shown in SEQ ID NO:45.
  • the second Fc peptide segment has the amino acid sequence shown in SEQ ID NO:46.
  • the first Fc peptide segment and the second Fc peptide segment are connected via a knob-into-hole structure.
  • the amino acid sequences of the first Fc peptide segment and the second Fc peptide segment may be the same or different, for example, when the amino acid sequences of the first Fc peptide segment and the second Fc peptide segment are the same, the two may be connected via a disulfide bond.
  • the first antigen binding region has the amino acid sequence shown in SEQ ID NO:47
  • the second antigen binding region has the amino acid sequence shown in SEQ ID NO:48 or 49.
  • Nucleic acids encoding the antibodies or antigen-binding fragments thereof or the bispecific binding molecules of the present invention are within the scope of the present invention, and those skilled in the art can easily obtain the corresponding nucleic acid sequences based on their amino acid sequences.
  • the present invention provides a nucleic acid molecule encoding the antibody or antigen binding fragment or the bispecific binding molecule described in the first aspect.
  • the antibody or antigen binding fragment encoded by the nucleic acid molecule can bind to human or monkey CD16A protein, effectively treat or prevent CD16A-mediated related diseases
  • the bispecific binding molecule encoded by the nucleic acid molecule can bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein, effectively treat or prevent CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the above nucleic acid molecule may further include at least one of the following additional technical features:
  • the nucleic acid molecule is DNA.
  • nucleic acids mentioned in the specification and claims of the present invention those skilled in the art should understand that the nucleic acids actually include complementary double-stranded Any one, or both.
  • nucleic acid sequence in this application includes DNA form or RNA form, and the disclosure of one of them means that the other is also disclosed.
  • the present invention proposes an expression vector, the expression vector carries the aforementioned nucleic acid molecule.
  • the expression vector may include an optional control sequence, the control sequence is operably connected to the nucleic acid molecule.
  • the control sequence is one or more control sequences that can guide the expression of the nucleic acid molecule in a host.
  • the expression vector proposed in the embodiment of the present invention can efficiently express the antibody or antigen-binding fragment in a large amount in a suitable host cell.
  • operably connected means connecting the exogenous gene to the vector so that the control elements in the vector, such as transcription control sequences and translation control sequences, etc., can play their intended function of regulating the transcription and translation of the exogenous gene.
  • control elements in the vector such as transcription control sequences and translation control sequences, etc.
  • the nucleic acid molecules can be directly or indirectly connected to the control elements on the vector, as long as these control elements can control the translation and expression of the nucleic acid molecules.
  • these control elements can come directly from the vector itself, or they can be exogenous, that is, not from the vector itself.
  • nucleic acid molecules used to encode antibodies or antigen-binding fragments can be inserted into different vectors separately and independently, and it is common to insert them into the same vector.
  • Commonly used vectors can be, for example, plasmids, bacteriophages, etc.
  • Plasmid-X plasmid Plasmid-X plasmid.
  • the present invention proposes a method for preparing the above-mentioned antibody or antigen-binding fragment or bispecific binding molecule, comprising: introducing the above-mentioned expression vector into cells; culturing the cells under conditions suitable for protein expression and secretion to obtain the antibody or antigen-binding fragment or bispecific binding molecule.
  • the method proposed according to some specific embodiments of the present invention can effectively obtain the antibody or antigen-binding fragment or bispecific binding molecule in large quantities in vitro.
  • the above method for preparing the above-mentioned antibody or antigen-binding fragment or bispecific binding molecule may also include at least one of the following additional technical features:
  • the cells are not particularly limited, and either prokaryotic cells or eukaryotic cells can be used.
  • the cell is a eukaryotic cell.
  • the eukaryotic cell is a mammalian cell.
  • the expression efficiency of the recombinant antibody is higher.
  • the present invention provides a recombinant cell, wherein the recombinant cell contains the aforementioned nucleic acid, or expression vector, or is capable of expressing the aforementioned antibody or antigen-binding fragment or the bispecific binding molecule.
  • the recombinant cell is obtained by transfecting or transforming the expression vector.
  • the recombinant cell can efficiently and massively express the above-mentioned antibody or antigen-binding fragment or the bispecific binding molecule under appropriate conditions.
  • the recombinant cells of the present invention are not particularly limited and may be prokaryotic cells, eukaryotic cells or bacteriophages.
  • the prokaryotic cells may be Escherichia coli, Bacillus subtilis, Streptomyces or Proteus mirabilis, etc.
  • the eukaryotic cells include fungi such as Pichia pastoris, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Trichoderma, insect cells such as armyworms, plant cells such as tobacco, mammalian cells such as BHK cells, CHO cells, COS cells, myeloma cells, etc.
  • the recombinant cells of the present invention are preferably mammalian cells, including BHK cells, CHO cells, NSO cells or COS cells, and do not include animal germ cells, fertilized eggs or embryonic stem cells.
  • suitable conditions refer to conditions suitable for the expression of the antibody or antigen-binding fragment or the bispecific binding molecule described in this application. It is easily understood by those skilled in the art that the conditions suitable for the expression of the antibody or antigen-binding fragment or the bispecific binding molecule include but are not limited to suitable transformation or transfection methods, suitable transformation or transfection conditions, healthy host cell states, suitable host cell density, suitable cell culture environment, and suitable cell culture time. "Suitable conditions” are not particularly limited, and those skilled in the art can optimize the most suitable conditions for the expression of the antibody or antigen-binding fragment according to the specific environment of the laboratory.
  • the present invention proposes an immunoconjugate, including the above-mentioned antibody or antigen binding fragment or the bispecific binding molecule, and a therapeutic agent.
  • the antibody or antigen binding fragment of the embodiment of the present invention can effectively bind to CD16A protein, and the bispecific binding molecule can bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein, effectively treat or prevent CD16A and BCMA, or CD16A and B7H6-mediated related diseases, therefore, the immunoconjugate containing the antibody or antigen binding fragment can also bind to human or monkey CD16A protein, and the immunoconjugate containing the bispecific binding molecule can also bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein, and the immunoconjugate has good prevention and/or treatment of CD16A-mediated diseases, or CD16A and BCMA, or CD16A and B
  • the present invention proposes a composition, including the above-mentioned antibody or antigen-binding fragment, bispecific binding molecule, nucleic acid molecule, expression vector or recombinant cell.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein, and the bispecific binding molecule can bind to human or monkey CD16A protein and BCMA protein, or to human or monkey CD16A protein and B7H6 protein, and effectively inhibit the proliferation of tumor cells.
  • the composition containing the above-mentioned substances can also effectively bind to human or monkey CD16A protein, Or it is combined with human or monkey CD16A protein and BCMA protein, or with human or monkey CD16A protein and B7H6 protein, and has good effects in preventing and/or treating CD16A-mediated diseases, or CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the type of the composition is not particularly limited and can be a food composition or a pharmaceutical composition.
  • compositions of the present invention may also be combined with each other or with one or more other therapeutic compounds for administration, for example, with a chemotherapeutic agent. Therefore, the composition may also contain a chemotherapeutic agent.
  • the antibody or antigen binding fragment thereof or immunoconjugate of the present invention may also be combined with a second therapeutic agent, exemplary agents of which include but are not limited to other agents that inhibit CD16A activity (including other antibodies or antigen binding fragments thereof, peptide inhibitors, small molecule antagonists, etc.) and/or agents that interfere with CD16A upstream or downstream signal transduction.
  • composition includes combinations separated in time and/or space, as long as they can work together to achieve the purpose of the present invention.
  • the components contained in the composition can be administered to the subject as a whole, or separately.
  • each component can be administered to the subject simultaneously or sequentially.
  • the present invention proposes a drug, including the above-mentioned antibody or antigen binding fragment, bispecific binding molecule, nucleic acid molecule, expression vector, recombinant cell or composition.
  • the antibody or antigen binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein, and the bispecific binding molecule can bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein.
  • a drug containing an effective amount of the antibody or antigen binding fragment or the active ingredient of the bispecific binding molecule or a series of substances thereof can also effectively bind to human or monkey CD16A protein, or bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein, and has good prevention and/or treatment of CD16A-mediated diseases, or CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the above-mentioned medicine may further include at least one of the following additional technical features:
  • the drug may further include a pharmaceutically acceptable carrier.
  • the term "effective amount” or “effective dose” refers to an amount that can produce a function or activity on humans and/or animals and can be accepted by humans and/or animals.
  • the effective amount of the antibody or antigen-binding fragment or the bispecific binding molecule of the present invention may vary with the mode of administration and the severity of the disease to be treated.
  • the selection of the preferred effective amount can be determined by a person of ordinary skill in the art based on various factors (e.g., through clinical trials).
  • the factors include, but are not limited to: pharmacokinetic parameters of the active ingredient such as bioavailability, metabolism, half-life, etc.; the severity of the disease to be treated, the patient's weight, the patient's immune status, the route of administration, etc. For example, several divided doses may be administered daily, or the dose may be reduced proportionally, depending on the urgency of the treatment situation.
  • pharmaceutically acceptable ingredients are suitable for use in humans and/or mammals without excessive adverse side effects (such as toxicity, irritation and allergic reactions), i.e., substances with a reasonable benefit/risk ratio.
  • pharmaceutically acceptable carrier refers to a carrier for administration of a therapeutic agent, including various excipients and diluents.
  • the medicine of the present invention contains a safe and effective amount of the active ingredient of the present invention and a pharmaceutically acceptable carrier.
  • Such carriers include (but are not limited to): saline, buffer, glucose, water, glycerol, ethanol, and combinations thereof.
  • the drug preparation should match the mode of administration, wherein the mode of administration can be oral administration, nasal administration, intradermal administration, subcutaneous administration, intramuscular administration, intravenous administration or intraperitoneal administration, and the dosage form of the medicine of the present invention is injection, oral preparation (tablet, capsule, oral liquid), transdermal agent, sustained release agent.
  • it is prepared by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • the medicine is preferably manufactured under sterile conditions.
  • the antibody or antigen-binding fragment can be administered by intravenous infusion or injection or intramuscular or subcutaneous injection.
  • anti-CD16A monoclonal antibody or bispecific binding molecule herein can also be prepared as a part of a kit or other diagnostic reagent as needed.
  • the present invention proposes a kit, the kit containing the above-mentioned antibody or antigen-binding fragment thereof, bispecific binding molecule, nucleic acid molecule, expression vector or recombinant cell.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein, and the bispecific binding molecule can bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein.
  • the kit containing the antibody or antigen-binding fragment can effectively detect the human or monkey CD16A protein qualitatively or quantitatively
  • the kit containing the bispecific binding molecule can effectively detect the human or monkey CD16A protein and BCMA protein, or the human or monkey CD16A protein and B7H6 protein qualitatively or quantitatively.
  • the kit provided by the present invention can be used, for example, for immunoblotting, immunoprecipitation, etc., which involve using human or monkey CD16A and antibody specific binding performance to detect the kit.
  • kits may contain any one or more of the following: antagonists, anti-CD16A antibodies or drug reference materials; protein purification columns; immunoglobulin affinity purification buffers; cell assay diluents; instructions or literature, etc.
  • Anti-CD16A antibodies can be used in different types of diagnostic tests, such as in vitro or in vivo detection of various diseases or the presence of drugs, toxins or other proteins, for example, by testing the serum or blood of a subject to test related diseases, or for scientific research, using the kit to detect human or monkey CD16A protein, or human or monkey CD16A protein and BCMA protein, or human or monkey CD16A protein and B7H6 protein in the sample to be tested.
  • the related diseases may include CD16A related diseases, such as autoimmune diseases or cancer.
  • the antibodies or antigen binding fragments provided herein can also be used for radioimmunoassay and radioimmunotherapy of the above diseases.
  • the bispecific binding molecules are also applicable and will not be repeated here.
  • the kit may also include conventional reagents for detecting CD16A, or CD16A and BCMA, or CD16A and B7H6, such as coating solution and the like.
  • the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment nucleic acid molecule, expression vector, recombinant cell or composition in the preparation of a drug, which is used to prevent and/or treat CD16A-mediated related diseases.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein, so a drug containing an effective amount of the antibody or antigen-binding fragment or a series of substances thereof can also effectively bind to human or monkey CD16A protein, and has a good effect of preventing and/or treating CD16A-mediated diseases, or CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the above-mentioned use of preparing a medicine may also include at least one of the following additional technical features:
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the present invention proposes the use of the aforementioned bispecific binding molecules, nucleic acid molecules, expression vectors, recombinant cells or compositions in the preparation of drugs, which are used to prevent and/or treat CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the bispecific binding molecules of some specific embodiments of the present invention can bind to human or monkey CD16A protein and BCMA protein, or to human or monkey CD16A protein and B7H6 protein, therefore, the drug containing an effective amount of the active ingredient of the bispecific binding molecule or a series of substances thereof can also effectively bind to human or monkey CD16A protein and BCMA protein, or to human or monkey CD16A protein and B7H6 protein, and has a good effect of preventing and/or treating CD16A and BCMA, or CD16A and B7H6-mediated related diseases.
  • the above-mentioned use of preparing a medicine may also include at least one of the following additional technical features:
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the above-mentioned antibody or antigen-binding fragment, nucleic acid molecule, expression vector or recombinant cell in the preparation of a kit for detecting CD16A.
  • the antibody or antigen-binding fragment of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein and block the binding of the CD16A protein to its receptor. Therefore, the antibody or antigen-binding fragment can be used to prepare a kit for detecting CD16A protein, and the kit can effectively perform qualitative or quantitative detection of human or monkey CD16A protein.
  • the present invention proposes the use of the aforementioned bispecific binding molecules, nucleic acid molecules, expression vectors or recombinant cells in the preparation of a kit for detecting CD16A and/or BCMA, or CD16A and/or B7H6.
  • the bispecific binding molecules of some specific embodiments of the present invention can effectively bind to human or monkey CD16A protein and BCMA protein, or bind to human or monkey CD16A protein and B7H6 protein, therefore, the bispecific binding molecules can be used to prepare a kit for detecting CD16A and/or BCMA, or CD16A and/or B7H6, and the kit can effectively perform qualitative or quantitative detection of human or monkey CD16A and/or BCMA, or CD16A and/or B7H6.
  • the present invention provides a method for treating or preventing CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases.
  • the method comprises administering to a subject at least one of the following: 1) the antibody or antigen-binding fragment described above; 2) the bispecific binding molecule described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; 5) the recombinant cell described above; 6) the composition described above; and 7) the drug described above.
  • the bispecific binding molecule can effectively bind to human or monkey CD16A protein and BCMA protein, or to human or monkey CD16A protein and B7H6 protein, and the antibody or antigen-binding fragment can bind to human or monkey CD16A protein, and can effectively treat or prevent CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases, preferably autoimmune diseases or cancer. Therefore, the method according to an embodiment of the present invention can effectively treat or prevent CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases, such as autoimmune diseases or cancer.
  • the above method for treating or preventing a disease may further include at least one of the following additional technical features:
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin dependence Type 2 diabetes, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis, and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for diagnosing CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases.
  • it includes using at least one of the following to detect CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested: 1) the antibody or antigen binding fragment described above; 2) the bispecific binding molecule described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; and 5) the recombinant cell described above, based on the detection result of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6, determine the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested.
  • the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, or antibodies or antigen-binding fragments expressed by recombinant cells proposed in the present application can effectively bind to human or monkey CD16A protein, and the bispecific binding molecules, or nucleic acid molecules, expression vectors, or bispecific binding molecules expressed by recombinant cells can effectively bind to CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • the method described in the present application can effectively detect the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample derived from the subject, and can effectively diagnose related diseases caused by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6F.
  • the above method for diagnosing a disease may further include at least one of the following additional technical features:
  • the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample is not less than the minimum standard for disease, which is an indication that the test sample is derived from a patient suffering from a disease related to CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • the value of the minimum standard can be determined by comparative analysis and verification of the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in a large number of individuals suffering from the disease related to CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 and a large number of healthy individuals.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for staging CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6F-mediated related diseases.
  • it includes using at least one of the following to detect CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested: 1) the antibody or antigen binding fragment described above; 2) the bispecific binding molecule described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; and 5) the recombinant cell described above, based on the detection result of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6, determine the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested.
  • the bispecific binding molecules proposed in the present application, or the bispecific binding molecules expressed by nucleic acid molecules, expression vectors, or recombinant cells can effectively bind to human or monkey CD16A and/or BCMA, or CD16A and/or B7H6, and the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, or antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD16A protein.
  • the method described in the present application can effectively detect the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample derived from the subject, and evaluate the stage of the related disease caused by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 based on the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • the above method for staging a disease may further include at least one of the following additional technical features:
  • the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample is not lower than the standard level of stage IV tumor, which indicates that the test sample is derived from a patient with stage IV tumor.
  • the content of BCMA, or CD16A and/or B7H6 is between the standard levels of tumor stage IV and stage III, which indicates that the sample to be tested is derived from a patient with a tumor stage III; the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested is between the standard levels of tumor stage III and stage II, which indicates that the sample to be tested is derived from a patient with a tumor stage II; the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested is between the standard levels of tumor stage I and stage II, which indicates that the sample to be tested is derived from a patient with a tumor stage I.
  • the levels of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 when the tumor is at stage I, stage II, stage III, or stage IV vary depending on the type of tumor, and to determine the stage of the tumor, it is only necessary to compare the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested with the standard level of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 at the corresponding tumor stage, or to compare the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested with the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in a sample from an individual or group of individuals with a known stage of the disease.
  • the values of the standard levels of tumor stages I, II, III, and IV can be determined by comparative analysis and verification of the differences in the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in a large number of test samples from individuals suffering from the angiogenesis-related diseases and a large number of healthy individuals.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes a method for evaluating the prognosis of related diseases mediated by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • it includes using at least one of the following to detect CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested: 2) the bispecific binding molecule described above; 2) the antibody or antigen binding fragment described above; 3) the nucleic acid molecule described above; 4) the expression vector described above; and 5) the recombinant cell described above, based on the detection result of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6, determine the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the sample to be tested.
  • CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 has an important influence on cancer.
  • the prognosis of such diseases can be effectively evaluated by monitoring the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in their tissues or excreta, such as peripheral blood, urine, etc.
  • the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the subject before and after treatment can be compared, or the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the subject after treatment can be compared with the level of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in normal individuals or diseased individuals, etc.
  • the bispecific binding molecules proposed in the present application, or the bispecific binding molecules expressed by nucleic acid molecules, expression vectors or recombinant cells can effectively bind to CD16A and/or BCMA, or CD16A and/or B7H6, and the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD16A.
  • the method described in the present application can effectively detect the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample derived from the subject, and evaluate the prognosis of related diseases caused by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 based on the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • the above method for evaluating disease prognosis may further include at least one of the following additional technical features:
  • the sample to be tested is derived from a patient suffering from a disease mediated by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 before or after treatment.
  • the sample to be tested includes at least one of the following: blood, saliva, sweat, tissue, cell, blood, serum, plasma, feces and urine.
  • the prognostic effect of CD16A, CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases is determined based on the content of CD16A, CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample of a patient suffering from CD16A, CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases before or after the treatment.
  • a decrease in the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in a test sample of a patient suffering from a CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related disease after treatment is an indication of a good prognosis for the patient.
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin dependence Type 2 diabetes, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis, and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the aforementioned bispecific binding molecules, antibodies or antigen binding fragments, nucleic acid molecules, expression vectors, recombinant cells, compositions or drugs in the treatment or prevention of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases.
  • the bispecific binding molecules have high binding activity with CD16A and/or BCMA, or CD16A and/or B7H6, and the antibodies or antigen binding fragments can effectively bind to human or monkey CD16A, and can effectively treat or prevent CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases.
  • the above-mentioned use may further include at least one of the following additional technical features:
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the present invention proposes the use of the aforementioned bispecific binding molecules, antibodies or antigen-binding fragments, nucleic acid molecules, expression vectors or recombinant cells in diagnosing CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases, staging CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases, or evaluating CD16A, or evaluating the prognosis of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6-mediated related diseases.
  • the bispecific binding molecules proposed in the present application or the bispecific binding molecules expressed by nucleic acid molecules, expression vectors or recombinant cells can effectively bind to CD16A and/or BCMA, or CD16A and/or B7H6, and the antibodies or antigen-binding fragments, or nucleic acid molecules, expression vectors, antibodies or antigen-binding fragments expressed by recombinant cells can effectively bind to human or monkey CD16A.
  • the method described in the present application can effectively detect the content of CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6 in the test sample derived from the subject, and can effectively diagnose, stage and evaluate the prognosis of related diseases mediated by CD16A, or CD16A and/or BCMA, or CD16A and/or B7H6.
  • the above-mentioned use may further include at least one of the following additional technical features:
  • the CD16A-mediated related diseases include autoimmune diseases.
  • the autoimmune disease includes at least one of the following: systemic lupus erythematosus, rheumatoid arthritis, systemic vasculitis, scleroderma, dermatomyositis, autoimmune hemolytic anemia, thyroid autoimmune disease, ulcerative colitis, chronic lymphocytic thyroiditis, hyperthyroidism, insulin-dependent diabetes mellitus, myasthenia gravis, ulcerative colitis, pernicious anemia with chronic atrophic gastritis, Goodpasture's syndrome, pemphigus vulgaris, pemphigoid, primary biliary cirrhosis, multiple sclerosis and acute idiopathic polyneuritis.
  • the CD16A and BCMA, or CD16A and B7H6-mediated related diseases include cancer.
  • the cancer includes at least one of the following: hemangioma, gastric cancer, liver cancer, lung cancer, breast cancer, colon cancer, nasopharyngeal cancer, bladder cancer, cervical cancer, prostate cancer, bone cancer, skin cancer, thyroid cancer, kidney cancer, esophageal cancer, melanoma, fibrosarcoma, rhabdomyosarcoma, astrocytoma, neuroblastoma and glioma.
  • the "subject” or “individual” referred to in the present invention generally refers to a mammal, such as a primate and/or a rodent, in particular a human, a monkey or a mouse.
  • the mouse anti-CD16A monoclonal antibody obtained in the present invention has higher CD16A protein binding activity than the existing CD16A monoclonal antibody, and the CD16A protein includes human CD16A protein and monkey CD16A protein.
  • the humanized antibody obtained by humanizing the mouse anti-CD16A monoclonal antibody also has higher CD16A protein binding activity than the existing CD16A monoclonal antibody
  • the CD16A protein includes human CD16A protein and monkey CD16A protein
  • the humanized antibody has lower immunogenicity, Higher safety and longer lasting effectiveness.
  • FIG1A is a graph showing the ELISA test results of different concentrations of mouse CD16A antibody (m40F5) binding to human CD16A 158F protein according to an embodiment of the present invention
  • FIG1B is a diagram showing the ELISA test results of different concentrations of mouse CD16A antibodies binding to human CD16A 158V protein according to an embodiment of the present invention
  • FIG1C is a diagram showing the ELISA test results of different concentrations of mouse CD16A antibodies binding to monkey CD16 protein according to an embodiment of the present invention.
  • FIG1D is a graph showing the ELISA test results of different concentrations of mouse CD16A antibodies binding to human CD16B NA1 protein according to an embodiment of the present invention.
  • FIG. 1E is a diagram showing the ELISA test results of different concentrations of mouse CD16A antibodies binding to human CD16B NA2 protein according to an embodiment of the present invention
  • FIG1F is a diagram showing the ELISA test results of different concentrations of mouse CD16A antibodies binding to human CD16B SH protein according to an embodiment of the present invention.
  • FIG2A is a diagram showing the detection results of different concentrations of mouse CD16A antibodies binding to human CHO cells overexpressing human CD16A protein according to an embodiment of the present invention
  • FIG2B is a diagram showing the detection results of different concentrations of mouse CD16A antibodies binding to human CHO cells overexpressing cynomolgus monkey CD16A protein according to an embodiment of the present invention
  • FIG3A is a diagram showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to human CD16A 158F protein according to an embodiment of the present invention
  • 3B is a diagram showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to human CD16A 158V protein according to an embodiment of the present invention
  • 3C is a diagram showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to monkey CD16 protein according to an embodiment of the present invention
  • FIG3D is a diagram showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to human CD16B NA1 protein according to an embodiment of the present invention
  • 3E is a diagram showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to human CD16B NA2 protein according to an embodiment of the present invention
  • FIG3F is a graph showing the ELISA test results of different concentrations of humanized CD16A antibody (h40F5) binding to human CD16B SH protein according to an embodiment of the present invention
  • FIG4A is a graph showing the detection results of different concentrations of CD16A ⁇ BCMA bispecific antibodies binding to human CD16A protein according to an embodiment of the present invention
  • FIG4B is a graph showing the detection results of different concentrations of CD16A ⁇ BCMA bispecific antibodies binding to human BCMA protein according to an embodiment of the present invention.
  • FIG5 is a graph showing the killing test results of NCI-H929 cells by CD16A ⁇ BCMA bispecific antibodies of different concentrations according to an embodiment of the present invention.
  • FIG6A is a graph showing the detection results of CD16A ⁇ B7H6 bispecific antibodies of different concentrations binding to human CD16A protein according to an embodiment of the present invention
  • FIG6B is a graph showing the detection results of different concentrations of CD16A ⁇ B7H6 bispecific antibodies binding to human B7H6 protein according to an embodiment of the present invention.
  • FIG. 7 is a graph showing the killing test results of CD16A ⁇ BCMA bispecific antibodies of different concentrations on HCT-15 cells according to an embodiment of the present invention.
  • first and second are used for descriptive purposes only and should not be understood as indicating or implying relative importance or implicitly indicating the number of the indicated technical features. Therefore, the features defined as “first” and “second” may explicitly or implicitly include one or more of the features. Further, in the description of the present invention, unless otherwise specified, the meaning of "plurality” is two or more.
  • any values of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values should be understood to include values close to these ranges or values.
  • the endpoint values of each range, the endpoint values of each range and the individual point values, and the individual point values can be combined with each other to obtain one or more new numerical ranges, which should be regarded as specifically disclosed in this article.
  • the antibody or antigen-binding fragment of the present invention is usually prepared by a biosynthetic method. Based on the nucleotide sequence of the present invention, a person skilled in the art can easily prepare the encoding nucleic acid of the present invention by various known methods. These methods include, but are not limited to, PCR, DNA artificial synthesis, etc. For specific methods, see J. Sambrook, "Molecular Cloning Laboratory Guide”.
  • the antibody or antigen-binding fragment of the present invention is usually prepared by a biosynthetic method.
  • a person skilled in the art can easily prepare the encoding nucleic acid of the present invention by various known methods. These methods include but are not limited to: PCR, DNA artificial synthesis, etc. For specific methods, please refer to J. Sambrook, "Molecular Cloning Laboratory Guide”.
  • the encoding nucleic acid sequence of the present invention can be constructed by synthesizing the nucleotide sequence in segments and then performing overlap extension PCR. Wherein, the antibody or antigen fragment is numbered and defined using the Kabat numbering system.
  • the term "monoclonal antibody” refers to an antibody that has a single antigen binding site.
  • double antibody refers to an antibody having two different antigen binding sites.
  • mutant or “variant” may refer to any naturally occurring or engineered molecule comprising one or more nucleotide or amino acid mutations.
  • CDR complementarity determining region
  • CDR sequence refers to the amino acid sequence in an antibody that is responsible for antigen binding, for example, generally including: amino acid residues around 23-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable region, and around 31-35B (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable region (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Health Service, National Institutes of Health, Bethesda, MD.
  • hypovariable loops e.g., amino acid residues around 26-32 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable region, and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable region (Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)).
  • identity is used to describe an amino acid sequence or nucleic acid sequence relative to a reference sequence, and the percentage of identical amino acids or nucleotides between two amino acid sequences or nucleic acid sequences is determined by conventional methods, for example, see Ausubel et al., eds. (1995), Current Protocols in Molecular Biology, Chapter 19 (Greene Publishing and Wiley-Interscience, New York); and the ALIGN program (Dayhoff (1978), Atlas of Protein Sequence and Structure 5: Suppl. 3 (National Biomedical Research Foundation, Washington, D.C.). There are many algorithms for aligning sequences and determining sequence identity, including the homology alignment algorithm of Needleman et al. (1970) J. Mol. Biol.
  • Computer programs that utilize these algorithms are also available and include, but are not limited to, ALIGN or Megalign (DNASTAR) software, or WU-B LAST-2 (Altschul et al., Meth. Enzym., 266:460-480 (1996)); or GAP, BESTFIT, BLAST Altschul et al., supra, FASTA, and TFASTA, available in the Genetics Computing Group (GCG) package, Version 8, Madison, Wisconsin, USA; and CLUSTAL in the PC/Gene program provided by Intelligenetics, Mountain View, California.
  • GCG Genetics Computing Group
  • those skilled in the art can replace, add and/or delete one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more) amino acids in the sequence of the present invention to obtain variants of the sequence of the antibody or its functional fragment. They are all considered to be included in the scope of protection of the present invention. For example, amino acids with similar properties are replaced in the variable region.
  • the variant sequence of the present invention can have at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% consistency (or homology) with the reference sequence.
  • the sequence consistency of the present invention can be measured using sequence analysis software.
  • the computer program BLAST with default parameters is used, especially BLASTP or TBLASTN.
  • the amino acid sequences described in the present invention are all shown in an N-terminal to C-terminal manner.
  • the monoclonal antibody of the present invention may be a full-length antibody or may only contain its functional fragment (e.g., Fab, F(ab')2 or scFv fragment), or may be modified to affect function.
  • the present invention includes anti-CD16A antibodies with modified glycosylation patterns. In some applications, it may be useful to modify to remove undesirable glycosylation sites, or antibodies in which fucose moieties are absent on the oligosaccharide chains to, for example, enhance antibody-dependent cellular cytotoxicity (ADCC) function. In other applications, galactosylation modification may be performed to alter complement-dependent cytotoxicity (CDC).
  • the “full-length antibody” refers to a tetrapeptide chain structure composed of two identical light chains and two identical heavy chains connected by interchain disulfide bonds, such as immunoglobulin G (IgG), immunoglobulin A (IgA), immunoglobulin M (IgM), immunoglobulin D (IgD) or immunoglobulin E (IgE).
  • the term "functional fragment” as used herein refers in particular to antibody fragments such as CDR-grafted antibodies, Fab, Fab', F(ab')2, Fv or scFv, nanobodies, or any fragments that should be able to increase half-life by chemical modification or by incorporation into liposomes, such as the addition of poly(alkylene) glycols, such as polyethylene glycol (“PEGylation, PEGylation”) (known as the PEGylated fragments of Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG) (“PEG” is polyethylene glycol), said fragment having CD16A binding activity.
  • PEGylation, PEGylation known as the PEGylated fragments of Fv-PEG, scFv-PEG, Fab-PEG, F(ab')2-PEG or Fab'-PEG
  • the functional fragment will be composed of or contain a partial sequence of the heavy chain variable region or light chain variable region of the antibody from which it is derived, and the partial sequence is sufficient to retain the same binding specificity and sufficient affinity as the antibody from which it is derived, preferably at least equal to 1/100 of the affinity of the antibody from which it is derived, and at least equal to 1/10 in a more preferred manner.
  • Such functional fragments will contain a minimum of 3 amino acids, and preferably 5, 10, 15, 25, 50 and 100 consecutive amino acids of the antibody sequence from which they are derived.
  • antigen-binding fragment used generally refers to an antigen-binding antibody fragment, which may include a portion of a complete antibody, generally an antigen-binding region or a variable region, such as, for example, CDR-grafted antibodies, Fab, Fab', F(ab')2, Fv or scFv, nanobodies, etc.
  • CDR transplanted antibody refers to transplanting the CDR of a monoclonal antibody of one species to the variable region of an antibody of another species.
  • the CDR of a mouse monoclonal antibody can be transplanted to the variable region of a human antibody to replace the human antibody CDR, so that the human antibody obtains the antigen binding specificity of the mouse monoclonal antibody while reducing its heterology.
  • Fab antibody generally refers to an antibody containing only Fab molecules, which are composed of VH and CH1 of the heavy chain and a complete light chain, with the light chain and the heavy chain connected by a disulfide bond.
  • the term “nanobody” (single domain antibody or VHH antibody), which was originally described as an antigen-binding "heavy chain antibody” (i.e., “antibody lacking light chains”), is used to The immunoglobulin (variable) domain (Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R.: “Naturally occurring antibodies devoid of light chains”; Nature 363, 446-448 (1993)) only comprises the heavy chain variable region (VH) and the conventional CH2 and CH3 regions, which specifically bind to the antigen through the heavy chain variable region.
  • VH heavy chain variable region
  • Fv antibody generally refers to an antibody consisting only of a light chain variable region (VL) and a heavy chain variable region (VH) linked by non-covalent bonds, and is the smallest functional fragment of an antibody that retains a complete antigen binding site.
  • single-chain antibody or “scFv” refers to a fragment consisting of the variable regions of the heavy and light chains of an antibody connected by a short peptide.
  • the "knob into hole structure” refers to a knob (knob) and a hole mutation formed in the CH3 region of the heavy chain constant region of an antibody, which facilitates the heavy chain to bite and form a heterodimer.
  • it is achieved by mutating the amino acids in the CH3 domain of the heavy chain constant region of human IgG1 (T366S, L368A, Y407V, and Y349C mutations in one chain, i.e., "hole”; T366W and S354C mutations in the other chain, i.e., "knob”).
  • the amino acid numbering here is numbered according to the Kabat numbering system.
  • the "T366S” means that the T amino acid at position 366 is replaced by the S amino acid according to the Kabat numbering system.
  • amino acid or nucleic acid sequences involved in the present invention are shown in Table 1.
  • HEK293T cells were plated in a T150 culture flask and cultured with complete DMEM medium. After overnight culture, endotoxin-free psPAX2, pMD2.G and pCDH-CMV-FCGR3A-IRES-puro (the coding sequence of human CD16A protein (SEQ ID NO: 37) (SEQ ID NO: 57) inserted between the multiple cloning sites of the pCDH-CMV-MCS-IRES-puro vector) or the coding sequence of cynomolgus monkey protein (SEQ ID NO: 38) (SEQ ID NO: 58) vector were added in a ratio of 7:3:10 to 1.5 mL Opti-MEM (Gibco, Cat.
  • the fully positive cells were CHO-K1 cells that overexpressed human CD16A or cynomolgus monkey CD16 that met the requirements.
  • anti-human CD16A monoclonal antibodies are produced by immunizing mice.
  • Experimental C57BL/6 mice, female, 6 weeks old the immune antigen is human CD16A extracellular segment protein (ACRO, CDA-H5220)
  • the first immunization is mixed with Freund's complete adjuvant (Sigma, F5881) and emulsified with the antigen and then immunized intraperitoneally, each mouse is intraperitoneally injected with 100 ⁇ g (please supplement the immunization method highlighted in yellow), and the subsequent immunization is mixed with the antigen with Ribi adjuvant system (Sigma, S6322) and then immunized intraperitoneally, wherein the first immunization is immunized once every 2 weeks, for a total of 3 times.
  • the serum of the immunized mice is taken for antibody titer ELISA detection, and the operation method is the conventional method in the art.
  • mice with high antibody titer in serum were selected for spleen cell fusion.
  • the selected mice were sprint immunized 72 hours before fusion, and a mixture of Ribi adjuvant system and the above antigens was intraperitoneally injected.
  • the spleen lymphocytes were fused with myeloma cells Sp2/0 cells (ATCC, CRL-8287) using an optimized PEG-mediated fusion step to obtain hybridoma cells.
  • the fused hybridoma cells were resuspended in HAT complete medium (RPMI-1640 medium containing 20% FBS, 1 ⁇ HAT and 1 ⁇ OPI), distributed in 96-well cell culture plates, and incubated at 37°C and 5% CO 2.
  • HAT complete medium was added on the 5th day after fusion, 50 ⁇ L/well. On the 7th to 8th day after fusion, according to the cell growth density, the medium was completely replaced, and the culture medium was HT complete medium (RPMI-1640 medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI), 200 ⁇ L/well.
  • HT complete medium RPMI-1640 medium containing 20% FBS, 1 ⁇ HT and 1 ⁇ OPI
  • wash 3 times with PBST (0.05% Tween 20-PBS, pH 7.2).
  • 300 ⁇ L of blocking buffer 1% BSA, 0.05% Tween20-PBS, pH 7.2
  • mouse antibody m40F5 or control antibody LS21 (WO2006/125668EN) to each well and incubate at room temperature for 1 hour.
  • Wash 3 times with PBST Add 100 ⁇ L of HRP-sheep anti-mouse IgG secondary antibody (boster, catalog number BA1051) diluted with blocking buffer to each well and incubate at room temperature for 1 hour.
  • Figure 1A shows that the mouse m40F5 antibody of the present invention can bind to human CD16A 158F
  • Figure 1B shows that the mouse m40F5 antibody of the present invention can also bind to human CD16A 158V
  • Figure 1C shows that the mouse m40F5 of the present invention can bind to cynomolgus monkey CD16
  • Figure 1D shows that the mouse m40F5 of the present invention does not bind to human CD16B NA1
  • Figure 1E shows that the mouse 40F5 of the present invention does not bind to human CD16B NA2
  • Figure 1F shows that the mouse 40F5 of the present invention does not bind to human CD16B SH .
  • the CHO-K1 cells overexpressing human CD16A or CHO-K1 cells overexpressing cynomolgus monkey CD16 obtained in Example 1 were diluted to 2 ⁇ 10 6 /mL with PBS, added to a 1.5mL EP tube at a volume of 100 ⁇ L/tube, 10 ⁇ L/tube of goat serum was added thereto, and blocked at 4°C for 30min. Gradient concentrations (5-fold dilution, final concentration up to 10 ⁇ g/mL) of CD16A antibody and control antibody mIgG were added and incubated at 4°C for 30min.
  • FIGS. 2A and 2B show that the mouse m40F5 antibody can bind to CHO-K1 cells overexpressing human CD16A and overexpressing cynomolgus monkey CD16, indicating that the mouse CD16A antibody can bind to the CD16A protein on the cell surface.
  • the total number of candidate hybridoma cells of the m40F5 antibody screened in the above example was cultured to 10 6 , and the cells were collected by centrifugation at 800 rpm for 10 minutes, and total RNA was extracted using a Trizol kit (Invitrogen); the total RNA was used as a template to synthesize a cDNA library (Invitrogen), and the cDNA was used as a template to PCR amplify the nucleic acid sequence of the variable region of the m40F5 antibody corresponding to the hybridoma cell.
  • the primer sequence used in the PCR amplification reaction was complementary to the first framework region or signal peptide region and constant region of the antibody variable region (for specific sequence selection, refer to Larrick, JW, et al., (1990) Scand. J. Immunol., 32, 121-128 and Coloma, JJ et al., (1991) BioTechniques, 11, 152-156).
  • PCR amplification was performed in a 50 ⁇ L reaction system, and 2 ⁇ L of cDNA, 5 ⁇ L of 10 ⁇ PCR buffer, 2 ⁇ L of upstream and downstream primers (5 ⁇ M), 2 ⁇ L of dNTP, 1 ⁇ L of Taq enzyme (Takara, Ex Taq), and 38 ⁇ L of H 2 O were added respectively; pre-denaturation at 95°C for 5 min, and temperature cycle was entered for PCR amplification.
  • the reaction conditions were: denaturation at 94°C for 30S, annealing at 58°C for 45S, extension at 72°C for 50S, a total of 32 cycles, and then extension at 72°C for 7 min.
  • the sequences of the heavy chain variable region (SEQ ID NO: 23) and light chain variable region (SEQ ID NO: 24) of mouse monoclonal antibody m40F5 were obtained.
  • Example 5 Based on the results obtained in Example 5, by comparing the IMGT human antibody heavy and light chain variable region germline gene database and MOE software, the heavy chain or light chain variable region germline genes with high homology to the mouse monoclonal antibody m40F5 were selected as templates, and the CDRs of the mouse monoclonal antibody were transplanted into the corresponding human templates to form a variable region sequence in the order of FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The amino acid residues were determined and annotated by the Kabat numbering system.
  • the heavy chain variable region sequence of the obtained humanized CD16A antibody h40F5 is shown in SEQ ID NO: 25, and the light chain variable region sequence is shown in SEQ ID NO: 26.
  • the nucleotide sequence encoding the heavy chain of the humanized antibody (SEQ ID NO: 39) and the nucleotide sequence encoding the light chain of the humanized antibody (SEQ ID NO: 40) were recombined into the pTT5 plasmid by molecular biology technology.
  • CD16A antibody was prepared by transiently transfecting ExpiCHO-S cells (Gibco, Catalog No. A29127) with the pTT5 vector carrying the humanized anti-human CD16A antibody h40F5 light and heavy chains.
  • the ExpiCHO-S cells were adjusted to a cell density of (3-4) ⁇ 10 6 /mL and cultured overnight at 37°C, 8% CO 2 , and 120 rpm shaking.
  • the cells grew to 7 ⁇ 10 6 ⁇ 1 ⁇ 10 7 /mL, and the survival rate was greater than 95%.
  • Transfection was prepared using fresh preheated ExpiCHO medium (Gibco, No.
  • A2910002 was diluted to 6 ⁇ 10 6 /mL, and the pTT5 plasmid carrying the humanized anti-human CD16A antibody h40F5 light chain and heavy chain and ExpiFectamine CHO transfection reagent (Gibco, No. A29129) were transfected into ExpiCHO-S cells at a molar ratio of 2:1, and cultured at 37°C, 8% CO 2 , and shaking at 120rpm. 18-22h after transfection, ExpiFectamine CHO Enhancer and ExpiCHO Feed were mixed and immediately added to the transfected cells, mixed, and cultured at 32°C, 5% CO 2 , and shaking at 120rpm.
  • the chromatography column was equilibrated with a pH 7.2 phosphate buffer, the supernatant was passed through the affinity chromatography column, eluted with an elution buffer (100 mM citric acid, pH 2.7), and finally concentrated and replaced with a PBS buffer.
  • the purified antibody was identified by SDS-PAGE to have a purity of more than 95%, and finally a humanized h40F5 antibody was obtained (the heavy chain is shown in SEQ ID NO: 35, and the light chain is shown in SEQ ID NO: 36).
  • the affinity of the humanized h40F5 antibody to human CD16A antigen, human CD16B and monkey CD16 antigen was tested by BIACORE. The results are shown in Table 2. The obtained humanized antibody has good affinity to CD16A antigen.
  • Human CD16A 158F ACRO biosystems, CDA-H5220
  • human CD16A 158V ACRO biosystems, CD8-H52H4
  • cynomolgus monkey CD16 ACRO biosystems, FC6-C52H9
  • human CD16B NA1 ACRO biosystems, CDB-H5227
  • human CD16B NA2 ACRO biosystems, CDB-H5222
  • human CD16B SH Seo Biological, 11046-H08H2
  • Figure 3A shows that the humanized h40F5 antibody of the present invention can bind to human CD16A 158F
  • Figure 3B shows that the humanized h40F5 antibody of the present invention can also bind to human CD16A 158V
  • Figure 3C shows that the humanized h40F5 of the present invention can bind to cynomolgus monkey CD16
  • Figure 3D shows that the humanized h40F5 of the present invention does not bind to human CD16B NA1
  • Figure 3E shows that the humanized h40F5 of the present invention does not bind to human CD16B NA2
  • Figure 3F shows that the humanized h40F5 of the present invention does not bind to human CD16B SH .
  • the inventors designed a bispecific antibody CD16A ⁇ BCMA, and tested the binding activity and cell killing ability of the bispecific antibody.
  • the antibody contains two monovalent units, one of which is in the form of anti-CD16A scFv-Fc, whose heavy chain variable region and light chain variable region amino acid sequences are from the sequence of the humanized antibody h40F5 obtained in Example 6 of the present invention, and the other monovalent unit is in the form of anti-BCMA scFv-Fc (sequence from US009273141B2), and the bispecific antibody is named CD16A ⁇ BCMA.
  • the bispecific antibody contains two polypeptide chains, namely: a heavy chain containing a CD16A single-chain antibody scFv (SEQ ID NO: 41) and a heavy chain containing a BCMA single-chain antibody scFv (SEQ ID NO: 42), wherein the heavy chain constant regions of the two chains are from human antibody IgG1. Since the molecule has a special asymmetric structure, different amino acid mutations are introduced in the constant regions of the two chains in order to reduce the generation of homodimers. At the same time, in order to prevent cross-linking activation caused by Fc ⁇ receptors, (L234A/L235A) mutations are also introduced in the heavy chain constant region.
  • the method for preparing the bispecific antibody refers to the method described in Example 6.2, and the bispecific antibody is prepared by combining the plasmid ratio (1:1 or other ratio) and undergoing one-step affinity purification, wherein the relevant sequence of the bispecific antibody CD16A ⁇ BCMA is shown in Table 3.
  • Human BCMA (ACRO biosystems, BCA-H522y) or human CD16A antigen (ACRO biosystems, CDD-H52W1) was diluted to 2 ⁇ g/mL with coating buffer (35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6), and 100 ⁇ L was added to each well of the enzyme-linked plate and incubated at 4°C overnight. After that, the plate was washed three times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2) was added to the plate and allowed to stand at room temperature for 2 hours. The plate was then washed three times with PBST.
  • coating buffer 35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6
  • 100 ⁇ L was added to each well of the enzyme-linked plate and incubated at 4°C overnight. After that, the plate was washed
  • NCI-H929 cells were labeled with CellTrace Violet (thermo, C34557) and the cell density was adjusted to 1 ⁇ 10 5 /mL.
  • the cell density of PBMC was adjusted to 1 ⁇ 10 6 /mL, and PBMC and labeled NCI-H929 cells were mixed at a ratio of 1:1 and added to a 96-well round bottom plate, and then the above-mentioned bispecific antibodies with gradient concentrations were added and mixed evenly. After incubation at 37°C for 24 hours, the cells were transferred to a flow tube through a 200-mesh nylon mesh, and the cells were tested 10 minutes after adding 7AAD. The killing efficiency was characterized by the ratio of CTV+7AAD+ cells.
  • the results in Figure 5 show that as the concentration of CD16A ⁇ BCMA bispecific antibodies increases, the killing efficiency of PBMC against NCI-H929 multiple myeloma cells gradually increases.
  • Examples 1-6 Based on the experimental results of Examples 1-6, the inventors designed a bispecific antibody CD16A ⁇ B7H6, and tested the binding activity and cell killing ability of the bispecific antibody.
  • the antibody contains two monovalent units, one of which is in the form of anti-CD16A scFv-Fc, in which the light chain variable region and the heavy chain variable region in CD16A scFv are from the humanized sequence of Example 6 of the present invention, and the other monovalent unit is in the form of anti-B7H6 scFv-Fc (the B7H6 scFv sequence is from CN114395045A).
  • This bispecific antibody is named CD16A ⁇ B7H6.
  • the bispecific antibody contains two polypeptide chains, namely: a heavy chain containing a CD16A single-chain antibody scFv (SEQ ID NO: 41) and a heavy chain containing a B7H6 single-chain antibody scFv (SEQ ID NO: 43). Since the molecule has a special asymmetric structure, different amino acid mutations are introduced into the constant regions of the two chains in order to reduce the generation of homodimers. At the same time, in order to prevent cross-linking activation caused by Fc ⁇ receptors, (L234A/L235A) mutations are also introduced into the heavy chain constant region.
  • the method for preparing the bispecific antibody of CD16A ⁇ B7H6 refers to Example 6.2, and the CD16A ⁇ B7H6 bispecific antibody is prepared by combining the plasmid ratio (1:1 or other ratios) and undergoing one-step affinity purification.
  • the relevant sequence of the bispecific antibody CD16A ⁇ B7H6 is shown in Table 4.
  • Human B7H6 (ACRO biosystems, B76-H52H8) or human CD16A antigen (ACRO biosystems, catalog number CDA-H5220) was diluted to 2 ⁇ g/mL with coating buffer (35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6), and 100 ⁇ L was added to each well of the enzyme-linked plate and incubated at 4°C overnight. After that, it was washed 3 times with PBST (0.05% Tween 20-PBS, pH 7.2). 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2) was added to the plate and allowed to stand at room temperature for 2 hours.
  • coating buffer 35 mM NaHCO 3 , 15 mM Na 2 CO 3 , pH 9.6
  • PBST 0.05% Tween 20-PBS, pH 7.2
  • 300 ⁇ L of blocking buffer (1% BSA, 0.05% Tween20-PBS, pH 7.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明提出了一种抗CD16A的抗体及其应用，该抗体包括分别如SEQ ID NO:1、2和3或者与SEQ ID NO:1、2和3具有至少95％同一性的氨基酸序列所示的重链可变区CDR1、CDR2、CDR3序列；和/或分别如SEQ ID NO:4、5和6或者与4、5和6具有至少95％同一性的氨基酸序列所示的轻链可变区CDR1、CDR2、CDR3序列。

Description

抗CD16A的抗体及其应用 技术领域
本发明涉及生物医药领域，具体地，涉及一种抗CD16A的抗体及应用。
背景技术
自然杀伤细胞(natural killer cells，NK细胞)是组成固有免疫系统的重要成员，与T细胞不同的是，NK细胞并不表达抗原特异性受体。NK细胞本身具有广谱的肿瘤杀伤能力，在增强抗体和T细胞应答中也起到了重要作用。目前，基于NK细胞的肿瘤免疫治疗形式多样，采用的手段也不尽相同。NK细胞数量减少或者功能受损与各种类型癌症的进展相关。“冷肿瘤”是免疫不敏感的，它表面表达的MHCⅠ类分子很少或没有，因此几乎不被T细胞识别，但是可以被NK细胞识别和杀伤，这一概念的引入提高了NK细胞在抗肿瘤免疫治疗中的地位。
CD16分子是NK细胞表面重要标志，它可以激活IgE NK细胞受体(FcεRIγ)和CD3ζ的免疫受体酪氨酸活化基序(ITAM)发生ADCC作用。因此，CD16靶点在基于NK细胞再导向的双特异性抗体中被优先选择。
CD16靶点在基于NK细胞再导向的双特异性抗体中被广泛选择(McCall et al.,1999,Gleason et al.,2014)。AFM13是针对CD16A和CD30分子的双特异性抗体，它可以促进NK细胞杀伤CD30+非霍奇金淋巴瘤细胞(Reusch et al.,2014,Pahl et al.,2018)。在另一些NK细胞相关的双特异性抗体中，研究者利用CD16、NKp46及肿瘤靶点来构建三功能抗体(NKCEs)。NKCEs相比临床治疗单抗有着更强的体外杀伤能力，同时其体内稳定性和肿瘤控制能力表现优异(Gauthier et al.,2019)。
人CD16可以分为CD16A和CD16B，其中CD16A主要在NK细胞表达。CD16B主要由多核粒细胞产生，同时在人血清中也存在可溶形式的受体。CD16A在人群中存在多个等位基因，例如CD16A在第158位存在多态性差异。CD16A158V相比CD16A158F与抗体Fc结构域具有更高的亲和力。CD16B在人群中也存在多态性差异，即CD16BNA1，CD16BNA2和CD16BSH。在之前的CD16抗体(如3G8)中基本都是识别CD16而非特异性识别CD16A的，因此在双特异性抗体或者多特异性抗体设计中为了特异性靶向NK细胞就需要开发识别CD16A的抗体。
发明内容
本申请是基于发明人对下列问题和事实的发现而提出的：
NK细胞本身具有广谱的肿瘤杀伤能力，在增强抗体和T细胞应答中也起到了重要作用，而CD16A蛋白主要在NK细胞中进行表达，CD16靶点在基于NK细胞再导向的双特异性抗体中被优先选择。
本申请的发明人成功地筛选到一种鼠源抗CD16A单克隆抗体，该单克隆抗体与人或猴CD16A蛋白具有较高的结合活性，此外，发明人对上述单克隆抗体的恒定区进行人源化，保留鼠源抗CD16A单克隆抗体的CDR，以获得嵌合抗体，更进一步地，将所述嵌合抗体的轻链可变区或重链可变区中的框架区进行人源化，得到抗CD16A的完全人源化抗体，所述人源化抗体不仅能够特异性的靶向结合人CD16A蛋白和猴CD16A蛋白，而且具有免疫原性低的特点，能够有效治疗和/或预防CD16A介导的相关疾病，如自身免疫疾病。
此外，利用所述抗CD16A抗体制备的双特异性结合分子或者多特异性结合分子同样能够特异性的靶向结合人CD16A蛋白和猴CD16蛋白，且通常地，基于双特异性结合分子或者多特异性结合分子的特异性，所述双特异性结合分子或者多特异性结合分子能够把NK细胞靶向到其它抗原，通过NK细胞介导的细胞杀伤作用来消除产生这种抗原的细胞，从而治疗多种疾病，如肿瘤。
因此，在本发明的第一方面，本发明提出了一种抗体或抗原结合片段。根据本发明的实施例，包括分别如SEQ ID NO:1、2和3或者与SEQ ID NO:1、2和3具有至少95％同一性的氨基酸序列所示的重链可变区CDR1、CDR2、CDR3序列；和/或分别如SEQ ID NO:4、5和6或者与4、5和6具有至少95％同一性的氨基酸序列所示的轻链可变区CDR1、CDR2、CDR3序列。根据本发明实施例的抗体或抗原结合片段能够与人或猴CD16A蛋白进行结合，有效治疗或预防CD16A介导的相关疾病。
根据本发明的实施例，上述抗体或抗原结合片段还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述抗体或抗原结合片段包括：重链FR区和轻链FR区中的至少之一。
根据本发明的实施例，所述重链FR区和轻链FR区的至少之一的至少一部分来自于人源抗体、灵长目源抗体和鼠源 抗体或其突变体中的至少之一。
根据本发明的实施例，所述抗体或抗原结合片段包括：分别如SEQ ID NO:7～10所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；或分别如SEQ ID NO:15～18所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一。
根据本发明的实施例，所述抗体或抗原结合片段包括：分别如SEQ ID NO:11～14所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一；或分别如SEQ ID NO:19～22所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一。
根据本发明的实施例，所述抗体或抗原结合片段包括：分别如SEQ ID NO:7～10所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；分别如SEQ ID NO:11～14所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一；或者分别如SEQ ID NO:15～18所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；分别如SEQ ID NO:19～22所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一。
根据本发明的实施例，所述抗体或抗原结合片段包括：如SEQ ID NO:23或SEQ ID NO:25所示的重链可变区；和/或如SEQ ID NO:24或SEQ ID NO:26所示的轻链可变区。
根据本发明的实施例，所述抗体或抗原结合片段包括：1)如SEQ ID NO:23所示的重链可变区，和如SEQ ID NO:24所示的轻链可变区；或2)如SEQ ID NO:25所示的重链可变区，和如SEQ ID NO:26所示的轻链可变区。
根据本发明的实施例，所述抗体或抗原结合片段含有重链恒定区和轻链恒定区的至少之一，所述重链恒定区和轻链恒定区的至少之一的至少一部分来自于人源抗体、灵长目源抗体和鼠源抗体或其突变体中的至少之一。
根据本发明的实施例，所述轻链恒定区和重链恒定区均来自于鼠源IgG抗体或其突变体或人源IgG抗体或其突变体。
根据本发明的实施例，所述轻链恒定区和重链恒定区均来自于鼠源IgG1抗体或其突变体或人源IgG1抗体或其突变体。
根据本发明的实施例，所述抗体具有如SEQ ID NO:27或29所示氨基酸序列的重链恒定区和/或如SEQ ID NO:28或30所示氨基酸序列的轻链恒定区。
根据本发明的实施例，所述抗体或抗原结合片段具有SEQ ID NO:31、33和35任一项所示氨基酸序列的重链和具有SEQ ID NO:32、34和36任一项所示氨基酸序列的轻链。
根据本发明的实施例，所述抗体或抗原结合片段具有SEQ ID NO:31所示氨基酸序列的重链和SEQ ID NO:32所示氨基酸序列的轻链；所述抗体或抗原结合片段具有SEQ ID NO:33所示氨基酸序列的重链和SEQ ID NO:34所示氨基酸序列的轻链；或所述抗体或抗原结合片段具有SEQ ID NO:35所示氨基酸序列的重链和SEQ ID NO:36所示氨基酸序列的轻链。
根据本发明的实施例，所述抗体或抗原结合片段包括单抗或多抗。
根据本发明的实施例，所述单抗包括Fv、单链抗体、Fab、单域抗体以及最小识别单位中的至少之一。
根据本发明的实施例，所述抗体或其抗原结合片段能够结合SEQ ID NO:37和/或38所示的氨基酸序列。
在本发明的第二方面，本发明提出了一种双特异性结合分子。根据本发明的实施例，包括第一结合区，所述第一结合区包含第一方面所述的抗体或抗原结合片段；和第二结合区，所述第二结合区具有BCMA或B7H6结合活性。根据本发明实施例的双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，可以将其应用于科学研究，或有效治疗或预防CD16A和BCMA，或者CD16A和B7H6介导的相关疾病。
本领域技术人员可以理解，所述第二结合区的结合活性并不受特别限制，也可以具有其它结合活性，只要所述双抗具有第一方面所述的抗体或抗原结合片段，且所述抗体或抗原结合片段和所述第二结合区均能够有效发挥功能即可。此外，也可以利用本申请所述的抗体或抗原结合片段制备更多特异性抗体，如三特异性、四特异性、五特异性，基于所述抗体的多特异性，本发明的抗体或抗原结合片段能够把NK细胞靶向到其它抗原，通过NK细胞介导的细胞杀伤作用来消除产生这种抗原的细胞。
根据本发明的实施例，上述双特异性结合分子还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述双特异性结合分子包括对称双特异性结合分子或不对称双特异性结合分子。
根据本发明的实施例，所述双特异性结合分子为非对称双特异性结合分子。
根据本发明的实施例，所述抗体或抗原结合片段为抗CD16A单链抗体。
根据本发明的实施例，所述第二结合区包括具有BCMA或B7H6结合活性的全长抗体、Fv、单链抗体、Fab、单域抗体以及最小识别单位中的至少之一。
根据本发明的实施例，所述第二结合区包括抗BCMA单链抗体或抗B7H6单链抗体。
根据本发明的实施例，所述抗CD16A单链抗体包括抗CD16A抗体轻链可变区和抗CD16A抗体重链可变区，所述抗CD16A抗体重链可变区具有SEQ ID NO:23或25所示的氨基酸序列，所述抗CD16A抗体轻链可变区具有如SEQ ID NO:24或26所示的氨基酸序列。
根据本发明的实施例，所述抗CD16A单链抗体进一步包括连接肽1，其中，所述连接肽1的N端与所述抗CD16A抗体重链可变区的C端相连，所述连接肽1的C端与所述抗CD16A抗体轻链可变区的N端相连；或所述连接肽1的N端与所述抗CD16A抗体轻链可变区的C端相连，所述连接肽1的C端与所述抗CD16A抗体重链可变区的N端相连。
根据本发明的实施例，所述抗BCMA单链抗体包括抗BCMA抗体轻链可变区和抗BCMA抗体重链可变区，所述抗BCMA抗体重链可变区具有SEQ ID NO:59所示的氨基酸序列，所述抗BCMA抗体轻链可变区具有如SEQ ID NO:60所示的氨基酸序列。
根据本发明的实施例，所述抗BCMA单链抗体进一步包括连接肽2，其中，所述连接肽2的N端与所述抗BCMA抗体重链可变区的C端相连，所述连接肽2的C端与所述抗BCMA抗体轻链可变区的N端相连；或所述连接肽2的N端与所述抗BCMA抗体轻链可变区的C端相连，所述连接肽2的C端与所述抗BCMA抗体重链可变区的N端相连。
根据本发明的实施例，所述抗B7H6单链抗体包括抗B7H6抗体轻链可变区和抗B7H6抗体重链可变区，所述抗B7H6抗体重链可变区具有SEQ ID NO:61所示的氨基酸序列，所述抗B7H6抗体轻链可变区具有如SEQ ID NO:62所示的氨基酸序列。
根据本发明的实施例，所述抗B7H6单链抗体进一步包括连接肽3，其中，所述连接肽3的N端与所述抗B7H6抗体重链可变区的C端相连，所述连接肽3的C端与所述抗B7H6抗体轻链可变区的N端相连；或所述连接肽3的N端与所述抗B7H6抗体轻链可变区的C端相连，所述连接肽3的C端与所述抗B7H6抗体重链可变区的N端相连。
根据本发明的实施例，所述连接肽1、连接肽2和连接肽3中的至少之一具有氨基酸序列(GGGGS)n，其中n为大于或等于1的整数，优选为1、2、3、4、5、6、7、8、9或10。本领域技术人员可以理解，本领域常规连接肽均可使用，如常规的柔性氨基酸片段或刚性氨基酸片段。
根据本发明的实施例，所述连接肽1、连接肽2和连接肽3中的至少之一具有SEQ ID NO:44所示的氨基酸序列。
根据本发明的实施例，所述抗CD16A单链抗体具有如SEQ ID NO:41所示的氨基酸序列。
根据本发明的实施例，所述抗BCMA单链抗体具有如SEQ ID NO:42所示的氨基酸序列。
根据本发明的实施例，所述抗B7H6单链抗体具有如SEQ ID NO:43所示的氨基酸序列。
根据本发明的实施例，所述第一抗原结合区进一步包括第一Fc肽段，所述第一Fc肽段的N端与所述抗体或抗原结合片段的C端相连。
根据本发明的实施例，所述第二抗原结合区进一步包括第二Fc肽段，所述第二Fc肽段的N端与所述抗BCMA单链抗体或所述抗B7H6单链抗体的C端相连。
根据本发明的实施例，所述第一Fc肽段具有SEQ ID NO:45所示的氨基酸序列。
根据本发明的实施例，所述第二Fc肽段具有SEQ ID NO:46所示的氨基酸序列。
根据本发明的实施例，所述第一Fc肽段和所述第二Fc肽段通过knob-into-hole结构进行连接。本领域技术人员可以理解，所述第一Fc肽段和所述第二Fc肽段的氨基酸序列可以相同或者不同，例如：当所述第一Fc肽段和所述第二Fc肽段的氨基酸序列相同时，两者可以通过二硫键进行连接。
根据本发明的实施例，所述第一抗原结合区具有SEQ ID NO:47所示的氨基酸序列，所述第二抗原结合区具有SEQ ID NO:48或49所示的氨基酸序列。
编码本发明的抗体或其抗原结合片段或者所述双特异性结合分子的核酸在本发明的范围内，根据其氨基酸序列，本领域技术人员能够很容易得到相应的核酸序列。
因此，在本发明的第三方面，本发明提供了一种核酸分子，所述核酸分子编码第一方面所述的抗体或抗原结合片段或所述双特异性结合分子。根据本发明一些具体实施方式中的核酸分子编码的抗体或抗原结合片段能够与人或猴CD16A蛋白进行结合，有效治疗或预防CD16A介导的相关疾病，所述核酸分子编码的双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，有效治疗或预防CD16A和BCMA，或者CD16A和B7H6介导的相关疾病。
根据本发明的实施例，上述核酸分子还可以包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述核酸分子为DNA。
需要说明的是，对于本发明说明书和权利要求书中所提及的核酸，本领域技术人员应当理解，实际包括互补双链的 任意一条，或者两条。为了方便，在本说明书和权利要求书中，虽然多数情况下只给出了一条链，但实际上也公开了与之互补的另一条链。另外，本申请中的核酸序列包括DNA形式或RNA形式，公开其中一种，意味着另一种也被公开。
在本发明的第四方面，本发明提出了一种表达载体，所述表达载体携带前面所述的核酸分子。所述表达载体可包括可选的控制序列，所述控制序列与所述核酸分子进行可操作地连接。其中，所述控制序列为可指导所述核酸分子在宿主中表达的一个或多个控制序列。本发明实施例所提出的表达载体可在适合的宿主细胞中高效大量表达所述抗体或抗原结合片段。
本文中“可操作地连接”是指将外源基因连接到载体上，使得载体内的控制元件，例如转录控制序列和翻译控制序列等等，能够发挥其预期的调节外源基因的转录和翻译的功能。在将上述核酸分子连接到载体上时，可以将核酸分子与载体上的控制元件直接或者间接相连，只要这些控制元件能够控制核酸分子的翻译和表达等即可。当然这些控制元件可以直接来自于载体本身，也可以是外源性的，即并非来自于载体本身。本领域技术人员可以理解，用来编码抗体或抗原结合片段的核酸分子，可以分别独立的插入到不同的载体上，常见的是插入到同一载体上。常用的载体例如可以为质粒、噬菌体等等。例如Plasmid-X质粒。
在本发明的第五方面，本发明提出了一种制备前面所述的抗体或抗原结合片段或双特异性结合分子的方法，包括：将前面所述的表达载体引入到细胞中；将所述细胞在适于蛋白表达和分泌的条件下进行培养，以便获得所述抗体或抗原结合片段或双特异性结合分子。根据本发明一些具体实施方式所提出的方法可以有效体外大量获得所述抗体或抗原结合片段或所述双特异性结合分子。
根据本发明的一些具体实施方式，上述制备前面所述的抗体或抗原结合片段或双特异性结合分子的方法还可以包括下列附加技术特征中的至少之一：
根据本发明的一些具体实施方式，所述细胞不受特别限制，原核细胞或真核细胞均可使用。
根据本发明的一些具体实施方式，所述细胞为真核细胞。
根据本发明的一些具体实施方式，所述真核细胞为哺乳动物细胞。根据本发明的一些具体实施例，当所述细胞为真核细胞，如哺乳动物细胞时所述重组抗体的表达效率较高。
在本发明的第六方面，本发明提出了一种重组细胞，所述重组细胞前面所述的核酸，或表达载体，或能够表达前面所述的抗体或抗原结合片段或所述双特异性结合分子。所述重组细胞是通过转染或者转化所述表达载体获得的。根据本发明的一些具体实施方式，所述重组细胞在合适条件下可高效并大量表达上述抗体或抗原结合片段或所述双特异性结合分子。
需要注意的是，本发明所述重组细胞不受特别限制，可以为原核细胞、真核细胞或噬菌体。所述原核细胞可以为大肠杆菌、枯草杆菌、链霉菌或奇异变形菌等。所述真核细胞包括巴斯德毕赤酵母、酿酒酵母、裂殖酵母、木霉等真菌，草地粘虫等昆虫细胞，烟草等植物细胞，BHK细胞、CHO细胞、COS细胞、骨髓瘤细胞等哺乳动物细胞。在一些实施例中，本发明所述重组细胞优选为哺乳动物细胞，包括BHK细胞、CHO细胞、NSO细胞或COS细胞，且不包括动物生殖细胞、受精卵或胚胎干细胞。
需要说明的是，本申请说明书中所述的“适合条件”，是指适合本申请所述抗体或抗原结合片段、或所述双特异性结合分子表达的条件。本领域技术人员容易理解的是，适合抗体或抗原结合片段或所述双特异性结合分子表达的条件包括但不限于合适的转化或转染方式、合适的转化或转条件、健康的宿主细胞状态、合适的宿主细胞密度、适宜的细胞培养环境、适宜的细胞培养时间。“适合条件”不受特别限制，本领域技术人员可根据实验室的具体环境，优化最适的所述抗体或抗原结合片段表达的条件。
在本发明的第七方面，本发明提出了一种免疫缀合物，包括前面所述的抗体或抗原结合片段或所述双特异性结合分子，和治疗剂。如前所述，本发明实施例的抗体或抗原结合片段能够有效CD16A蛋白进行结合，所述双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，有效治疗或预防CD16A和BCMA，或者CD16A和B7H6介导的相关疾病，因此，包含所述抗体或抗原结合片段的免疫缀合物同样能够与人或猴的CD16A蛋白进行结合，包含所述双特异性结合分子的免疫缀合物同样能够与人或猴CD16A蛋白和BCMA蛋白，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，所述免疫缀合物具有良好的预防和/或治疗CD16A介导的疾病，或者CD16A和BCMA，或者CD16A和B7H6介导的相关疾病效果。
在本发明的第八方面，本发明提出了一种组合物，包括前面所述的抗体或抗原结合片段、双特异性结合分子、核酸分子、表达载体或重组细胞。如前所述，本发明一些具体实施方式的所述抗体或抗原结合片段能够有效与人或猴CD16A蛋白进行结合，所述双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，并有效抑制肿瘤细胞的增殖，因此，包含上述物质的组合物同样可以有效与人或猴CD16A蛋白， 或者与人或猴CD16A蛋白和BCMA蛋白，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，具有良好的预防和/或治疗CD16A介导的疾病，或者CD16A和BCMA，或者CD16A和B7H6介导的相关疾病效果，所述组合物的种类不受特别限制，可以为食品组合物或药物组合物。
本发明的组合物也可以相互组合、或与一种或多种其它的治疗化合物组合给药，例如，与化疗剂组合给药。因此，所述组合物还可以含有化疗剂。本发明的抗体或其抗原结合片段、或免疫缀合物还可以与第二治疗剂组合，所述第二治疗剂的示例性试剂包括但不限于抑制CD16A活性的其他试剂(包括其他抗体或其抗原结合片段、肽抑制剂、小分子拮抗剂等)和/或干扰CD16A上游或下游信号转导的试剂。
需要注意的是，所述组合物包括在时间和/或空间上分开的组合，只要其能够共同作用以实现本发明的目的。例如，所述组合物中所含的成分可以以整体施用于受试者，或者分开施用于受试者。当所述组合物中所含的成分分开地施用于受试者时，各个成分可以同时或依次施用于受试者。
在本发明的第九方面，本发明提出了一种药物，包括前面所述的抗体或抗原结合片段、双特异性结合分子、核酸分子、表达载体、重组细胞或组合物。如前所述，本发明一些具体实施方式的所述抗体或抗原结合片段能够有效与人或猴CD16A蛋白进行结合，所述双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，因此，包含有效量的所述抗体或抗原结合片段或者所述双特异性结合分子的活性成分或其一系列物质的药物同样可以有效与人或猴CD16A蛋白进行结合，或者与人或猴CD16A蛋白和BCMA蛋白，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，具有良好的预防和/或治疗CD16A介导的疾病，或者CD16A和BCMA，或者CD16A和B7H6介导的相关疾病效果。
根据本发明的实施例，上述药物还可以进一步包括如下附加技术特征至少之一：
根据本发明的实施例，所述药物还可以包括药学上可接受的载体。
如本文所用，术语“有效量”或“有效剂量”是指可对人和/或动物产生功能或活性的且可被人和/或动物所接受的量。
本发明所述的抗体或抗原结合片段或所述双特异性结合分子的有效量可随给药的模式和待治疗的疾病的严重程度等而变化。优选的有效量的选择可以由本领域普通技术人员根据各种因素来确定(例如通过临床试验)。所述的因素包括但不限于：所述的活性成分的药代动力学参数例如生物利用率、代谢、半衰期等；患者所要治疗的疾病的严重程度、患者的体重、患者的免疫状况、给药的途径等。例如，由治疗状况的迫切要求，可每天给予若干次分开的剂量，或将剂量按比例地减少。
如本文所用，“药学上可接受的”的成分是适用于人和/或哺乳动物而无过度不良副反应(如毒性、刺激和变态反应)的，即具有合理的效益/风险比的物质。术语“药学上可接受的载体”指用于治疗剂给药的载体，包括各种赋形剂和稀释剂。
本发明的药物含有安全有效量的本发明的活性成分以及药学上可接受的载体。这类载体包括(但并不限于)：盐水、缓冲液、葡萄糖、水、甘油、乙醇、及其组合。通常药物制剂应与给药方式相匹配，其中，给药的方式可以为口服给药、经鼻给药、皮内给药、皮下给药、肌内给药或静脉给药或腹腔内给药，本发明的药物的剂型为注射剂、口服制剂(片剂、胶囊、口服液)、透皮剂、缓释剂。例如用生理盐水或含有葡萄糖和其他辅剂的水溶液通过常规方法进行制备。所述的药物宜在无菌条件下制造。所述抗体或抗原结合片段可通过静脉输注或注射或肌肉内或皮下注射来施用。
当然，本文中的抗CD16A单抗或双特异性结合分子还可以根据需要被制成试剂盒或者其他诊断性试剂的一部分。
在本发明的第十方面，本发明提出了一种试剂盒，所述试剂盒含有前面所述抗体或其抗原结合片段、双特异性结合分子、核酸分子、表达载体或重组细胞。如前所述，本发明一些具体实施方式的抗体或抗原结合片段能够有效与人或猴CD16A蛋白进行结合，所述双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，因此，包含所述抗体或抗原结合片段的试剂盒能够有效的对人或猴的CD16A蛋白进行定性或定量检测，包含所述双特异性结合分子的试剂盒能够有效的对人或猴CD16A蛋白和BCMA蛋白，或者人或猴CD16A蛋白和B7H6蛋白进行定性或定量检测。应用本发明提供的试剂盒，例如可以用于免疫印迹、免疫沉淀等涉及到利用人或猴CD16A和抗体特异性结合性能来检测的试剂盒等。这些试剂盒可包含下列中的任意一种或多种：拮抗剂、抗CD16A抗体或者药物参照材料；蛋白纯化柱；免疫球蛋白亲和纯化缓冲剂；细胞的测定稀释剂；说明书或者文献等。抗CD16A抗体可被用于不同类型的诊断测试，例如可以在体外或者体内检测各种各样的疾病或者药物、毒素或者其他蛋白等的存在，例如可以通过对受试者的血清或者血液进行检测，用来测试相关疾病，也可以进行科研研究，利用所述试剂盒检测待测样品中的人或猴CD16A蛋白，或者人或猴CD16A蛋白和BCMA蛋白，或者人或猴CD16A蛋白和B7H6蛋白。这 种相关疾病可包括CD16A相关疾病，例如自身免疫性疾病或者癌症。当然本文提供的抗体或抗原结合片段也可以用于上述疾病的放射免疫检测和放射免疫治疗等等。针对于上述应用场景，所述双特异性结合分子同样适用，此处不再累述。
所述试剂盒还可以包括常规用于检测CD16A，或者CD16A和BCMA，或者CD16A和B7H6的试剂，如包被液等。
在本发明的第十一方面，本发明提出了前面所述的抗体或其抗原结合片段核酸分子、表达载体、重组细胞或组合物在制备药物中的用途，所述药物用于预防和/或治疗CD16A介导的相关疾病。如前所述，本发明一些具体实施方式的所述抗体或抗原结合片段能够有效与人或猴CD16A蛋白进行结合，因此，包含有效量的所述抗体或抗原结合片段或其一系列物质的药物同样可以有效与人或猴CD16A蛋白进行结合，具有良好的预防和/或治疗CD16A介导的疾病，或者CD16A和BCMA，或者CD16A和B7H6介导的相关疾病效果。
根据本发明的实施例，上述制备药物的用途还可以包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
在本发明的第十二方面，本发明提出了前面所述的双特异性结合分子、核酸分子、表达载体、重组细胞或组合物在制备药物中的用途，所述药物用于预防和/或治疗CD16A和BCMA，或者CD16A和B7H6介导的相关疾病。如前所述，本发明一些具体实施方式的所述双特异性结合分子能够与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，因此，包含有效量的所述双特异性结合分子的活性成分或其一系列物质的药物同样可以有效与人或猴CD16A蛋白和BCMA蛋白，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，具有良好的预防和/或治疗CD16A和BCMA，或者CD16A和B7H6介导的相关疾病效果。
根据本发明的实施例，上述制备药物的用途还可以包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十三方面，本发明提出了前面所述的抗体或抗原结合片段、核酸分子、表达载体或重组细胞在制备试剂盒中的用途，所述试剂盒用于检测CD16A。如前所述，本发明一些具体实施方式的抗体或抗原结合片段能够有效与人或猴CD16A蛋白进行结合，并阻断所述CD16A蛋白与其受体进行结合，因此，所述抗体或抗原结合片段可以用于制备检测CD16A蛋白的试剂盒，所述试剂盒能够有效的对人或猴的CD16A蛋白进行定性或定量检测。
在本发明的第十四方面，本发明提出了前面所述的双特异性结合分子、核酸分子、表达载体或重组细胞在制备试剂盒中的用途，所述试剂盒用于检测CD16A和/或BCMA，或者，CD16A和/或B7H6。如前所述，本发明一些具体实施方式的双特异性结合分子能够有效与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，因此，所述双特异性结合分子可以用于制备检测CD16A和/或BCMA，或者，CD16A和/或B7H6的试剂盒，所述试剂盒能够有效的对人或猴的CD16A和/或BCMA，或者，CD16A和/或B7H6进行定性或定量检测。
在本发明的第十五方面，本发明提出了一种治疗或预防CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病的方法。根据本发明的实施例，所述方法包括向受试者施用以下中的至少之一：1)前面所述的抗体或抗原结合片段；2)前面所述的双特异性结合分子；3)前面所述的核酸分子；4)前面所述的表达载体；5)前面所述的重组细胞；6)前面所述的组合物；和7)前面所述的药物。如前所述，所述双特异性结合分子能够有效与人或猴CD16A蛋白和BCMA蛋白进行结合，或者与人或猴CD16A蛋白和B7H6蛋白进行结合，所述抗体或抗原结合片段能够与人或猴CD16A蛋白进行结合，能够有效治疗或预防CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病，优选为自身免疫性疾病或癌症，因此，根据本发明实施例的方法能够有效治疗或预防CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病，例如自身免疫性疾病或癌症。
根据本发明的实施例，上述治疗或预防疾病的方法还可以进一步包括如下附加技术特征至少之一：
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖 型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十六方面，本发明提出了一种诊断CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病的方法。根据本发明的实施例，包括使用下列中的至少之一对待测样品中的CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6进行检测：1)前面所述的抗体或抗原结合片段；2)前面所述的双特异性结合分子；3)前面所述的核酸分子；4)前面所述的表达载体；和5)前面所述的重组细胞，基于所述CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6的检测结果，确定所述待测样品中CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6的含量。本申请提出的所述抗体或抗原结合片段，或核酸分子、表达载体、重组细胞表达的抗体或抗原结合片段均可以有效与人或猴CD16A蛋白进行结合，所述双特异性结合分子，或核酸分子、表达载体、重组细胞表达的双特异性结合分子均可以有效与CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6进行结合，因此，采用本申请所述的方法可以有效检测来源于受试个体的待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量，并可以对CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6F引起的相关疾病进行有效诊断。
根据本发明的实施例，上述诊断疾病的方法还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量不低于患病的最低标准是待测样品来源于患有CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6引起的相关疾病的患者的指示。所述最低标准的值可以通过对大量患有所述CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6引起的相关疾病的个体和大量健康个体的待测样本中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量进行差异比较分析、以及验证，而确定下来。
根据本发明的实施例，所述待测样品包括下列中的至少之一：血液、唾液、汗液、组织、细胞、血液、血清、血浆、粪便和尿液。
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十六方面，本发明提出了一种对CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6F介导的相关疾病进行分期的方法。根据本发明的实施例，包括使用下列中的至少之一对待测样品中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6进行检测：1)前面所述的抗体或抗原结合片段；2)前面所述的双特异性结合分子；3)前面所述的核酸分子；4)前面所述的表达载体；和5)前面所述的重组细胞，基于所述CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的检测结果，确定所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量。本申请提出的所述双特异性结合分子，或核酸分子、表达载体、重组细胞表达的双特异性结合分子均可以有效与人或猴的CD16A和/或BCMA，或者CD16A和/或B7H6进行结合，所述抗体或抗原结合片段，或核酸分子、表达载体、重组细胞表达的抗体或抗原结合片段均可以有效与人或猴的CD16A蛋白进行结合，因此，采用本申请所述的方法可以有效检测来源于受试个体的待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6含量，并基于所述CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6含量对CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6引起的相关疾病所处的时期进行评估。
根据本发明的实施例，上述对疾病进行分期的方法还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量不低于肿瘤IV期患病的标准水平是待测样品来源于患有肿瘤IV期的患者的指示，所述待测样品中CD16A，或者CD16A和/或 BCMA，或者CD16A和/或B7H6的含量位于肿瘤IV期和III期患病的标准水平之间是待测样品来源于患有肿瘤III期的患者的指示；所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量处于肿瘤III期和II期患病的标准水平之间是待测样品来源于患有肿瘤II期的患者的指示；所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量处于I期和II期患病的标准水平之间是待测样品来源于患有肿瘤I期的患者的指示。本领域技术人员可以理解，所述的肿瘤I期、II期、III期、IV期患病时CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的水平根据肿瘤种类的不同而变化，判断肿瘤所述时期，只要将所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量与对应的该肿瘤阶段CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的标准水平进行对比即可知晓，或将所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量与已知患病时期的个体或群体来源的样品CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量进行对比。所述肿瘤I期、II期、III期、IV期标准水平的值可以通过对大量所述患有血管生成引起的相关疾病的个体和大量健康个体的待测样本中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量的差异进行比较分析、以及验证，而确定下来。
根据本发明的实施例，所述待测样品包括下列中的至少之一：血液、唾液、汗液、组织、细胞、血液、血清、血浆、粪便和尿液。
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十七方面，本发明提出了一种评估CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6介导的相关疾病预后的方法。根据本发明的实施例，包括使用下列中的至少之一对待测样品中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6进行检测：2)前面所述的双特异性结合分子；2)前面所述的抗体或抗原结合片段；3)前面所述的核酸分子；4)前面所述的表达载体；和5)前面所述的重组细胞，基于所述CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的检测结果，确定所述待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量。如前所述，CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量对癌症具有重要影响，患有相关疾病个体进行治疗后，通过监测其组织或排泄物，如外周血、尿液等中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量可以有效评估该类疾病的预后，例如，将治疗前后的受试者体内CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量进行比较，或将治疗后的受试者体内CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量与正常个体或患病个体的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6水平进行比较等方式，本申请提出的所述双特异性结合分子，或核酸分子、表达载体或重组细胞表达的双特异性结合分子均可以有效与CD16A和/或BCMA，或者CD16A和/或B7H6进行结合，所述抗体或抗原结合片段，或核酸分子、表达载体、重组细胞表达的抗体或抗原结合片段均可以有效与人或猴CD16A进行结合，因此，采用本申请所述的方法可以有效检测来源于受试个体的待测样品中CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量，并基于所述CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量对CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6引起的相关疾病的预后进行评估。
根据本发明的实施例，上述评估疾病预后的方法还可以进一步包括下列附加技术特征中的至少之一：
根据本发明的实施例，所述待测样品来源于治疗前或治疗后的患有CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6介导的相关疾病的患者。
根据本发明的实施例，所述待测样品包括下列中的至少之一：血液、唾液、汗液、组织、细胞、血液、血清、血浆、粪便和尿液。
根据本发明的实施例，基于所述治疗前或治疗后的患有CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6介导的相关疾病的患者的待测样品中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量，确定CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6介导的相关疾病的预后效果。
根据本发明的实施例，治疗后的患有CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6介导的相关疾病的患者的待测样品中的CD16A，或者CD16A和/或BCMA，或者CD16A和/或B7H6的含量下降是患者预后良好的指示。
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖 型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十八方面，本发明提出了本发明提出了前面所述的双特异性结合分子，抗体或抗原结合片段，核酸分子，表达载体、重组细胞，组合物或药物在治疗或预防CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病中的用途。如前所述，所述双特异性结合分子与CD16A和/或BCMA，或者，CD16A和/或B7H6均具有较高的结合活性，所述抗体或抗原结合片段能够与人或猴CD16A进行有效结合，能够有效治疗或预防CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病。
根据本发明的实施例，上述用途还可以进一步包括如下附加技术特征至少之一：
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
在本发明的第十九方面，本发明提出了前面所述的双特异性结合分子，抗体或抗原结合片段，核酸分子，表达载体或重组细胞在诊断CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病、对CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病进行分期或评估CD16A，或者评估CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病预后中的用途。如前所述，本申请提出的所述双特异性结合分子，或核酸分子、表达载体或重组细胞表达的双特异性结合分子均可以有效与CD16A和/或BCMA，或者，CD16A和/或B7H6进行结合，所述抗体或抗原结合片段，或核酸分子、表达载体、重组细胞表达的抗体或抗原结合片段均可以有效与人或猴CD16A进行结合，因此，采用本申请所述的方法可以有效检测来源于受试个体的待测样品中CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6含量，并可以对CD16A，或者CD16A和/或BCMA，或者，CD16A和/或B7H6介导的相关疾病进行有效诊断、疾病分期和疾病预后评估。
根据本发明的实施例，上述用途还可以进一步包括如下附加技术特征至少之一：
根据本发明的实施例，所述CD16A介导的相关疾病包括自身免疫性疾病。
所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
根据本发明的实施例，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
根据本发明的实施例，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
本发明中涉及的“受试者”或“个体”一般指哺乳动物，如灵长类动物和/或啮齿类动物，特别是人、猴或鼠。
本发明的有益效果：
1)本发明获得的所述鼠源的抗CD16A的单克隆抗体较现有CD16A单克隆抗体具有更高的CD16A蛋白结合活性，且所述CD16A蛋白包括人CD16A蛋白和猴CD16A蛋白。
2)将所述鼠源抗CD16A单克隆抗体进行人源化后获得的所述人源化抗体同样较现有CD16A单克隆抗体具有更高的CD16A蛋白结合活性，所述CD16A蛋白包括人CD16A蛋白和猴CD16A蛋白，且所述人源化抗体具有较低的免疫原性， 安全性更高，效力更加持久。
本发明的附加方面和优点将在下面的描述中部分给出，部分将从下面的描述中变得明显，或通过本发明的实践了解到。
附图说明
本发明的上述和/或附加的方面和优点从结合下面附图对实施例的描述中将变得明显和容易理解，其中：
图1A为根据本发明实施例的不同浓度的鼠源CD16A抗体(m40F5)结合人CD16A158F蛋白的ELISA检测结果图；
图1B为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人CD16A158V蛋白的ELISA检测结果图；
图1C为根据本发明实施例的不同浓度的鼠源CD16A抗体结合猴CD16蛋白的ELISA检测结果图；
图1D为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人CD16BNA1蛋白的ELISA检测结果图；
图1E为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人CD16BNA2蛋白的ELISA检测结果图；
图1F为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人CD16BSH蛋白的ELISA检测结果图；
图2A为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人过表达人CD16A蛋白的CHO细胞的检测结果图；
图2B为根据本发明实施例的不同浓度的鼠源CD16A抗体结合人过表达食蟹猴CD16A蛋白的CHO细胞的检测结果图；
图3A为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合人CD16A158F蛋白的ELISA检测结果图；
图3B为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合人CD16A158V蛋白的ELISA检测结果图；
图3C为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合猴CD16蛋白的ELISA检测结果图；
图3D为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合人CD16BNA1蛋白的ELISA检测结果图；
图3E为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合人CD16BNA2蛋白的ELISA检测结果图；
图3F为根据本发明实施例的不同浓度的人源化CD16A抗体(h40F5)结合人CD16BSH蛋白的ELISA检测结果图；
图4A为根据本发明实施例的不同浓度的CD16A×BCMA双特异性抗体结合人CD16A蛋白的检测结果图；
图4B为根据本发明实施例的不同浓度的CD16A×BCMA双特异性抗体结合人BCMA蛋白的检测结果图；
图5为根据本发明实施例的不同浓度的CD16A×BCMA双特异性抗体对NCI-H929细胞的杀伤检测结果图；
图6A为根据本发明实施例的不同浓度的CD16A×B7H6双特异性抗体结合人CD16A蛋白的检测结果图；
图6B为根据本发明实施例的不同浓度的CD16A×B7H6双特异性抗体结合人B7H6蛋白的检测结果图；以及
图7为根据本发明实施例的不同浓度的CD16A×BCMA双特异性抗体对HCT-15细胞的杀伤检测结果图。
具体实施方式
下面详细描述本发明的实施例。下面描述的实施例是示例性的，仅用于解释本发明，而不能理解为对本发明的限制。
需要说明的是，术语“第一”、“第二”仅用于描述目的，而不能理解为指示或暗示相对重要性或者隐含指明所指示的技术特征的数量。由此，限定有“第一”、“第二”的特征可以明示或者隐含地包括一个或者更多个该特征。进一步地，在本发明的描述中，除非另有说明，“多个”的含义是两个或两个以上。
在本文中所披露的范围的端点和任何值都不限于该精确的范围或值，这些范围或值应当理解为包含接近这些范围或值的值。对于数值范围来说，各个范围的端点值之间、各个范围的端点值和单独的点值之间，以及单独的点值之间可以彼此组合而得到一个或多个新的数值范围，这些数值范围应被视为在本文中具体公开。
为了更容易理解本发明，以下具体定义了某些技术和科学术语。除显而易见在本文件中的它处另有明确定义，否则本文中使用的所有其它技术和科学术语都具有本发明所属领域的一般技术人员通常理解的含义。氨基酸残基的缩写是本领域中所用的指代20个常用L-氨基酸之一的标准3字母和/或1字母代码。
本发明所述的抗体或抗原结合片段通常由生物合成的方法制备。根据本发明所述的核苷酸序列，本领域技术人员可方便地用各种已知方法制得本发明的编码核酸。这些方法例如但不限于：PCR，DNA人工合成等，具体的方法可参见J.萨姆布鲁克，《分子克隆实验指南》。
本发明所述的抗体或抗原结合片段通常由生物合成的方法制备。根据本发明所述的核苷酸序列，本领域技术人员可方便地用各种已知方法制得本发明的编码核酸。这些方法例如但不限于：PCR，DNA人工合成等，具体的方法可参见J.萨姆布鲁克，《分子克隆实验指南》。作为本发明的一种实施方式，可通过分段合成核苷酸序列再进行重叠延伸PCR的方法来构建本发明的编码核酸序列。其中，所述抗体或抗原片段是采用Kabat编号系统进行编号和定义的。
本文中，所述“单抗”是指具有单一抗原结合位点的抗体。
本文中，所述“双抗”是指具有两个不同抗原结合位点的抗体。
在本文中，术语“突变体”或“变体”可以指包含对任何天然存在的或工程化的分子进行包含一个或多个核苷酸或氨基酸突变获得的分子。
术语“互补决定区”或“CDR”或“CDR序列”是指抗体中负责抗原结合的氨基酸序列，例如，通常包括：轻链可变区中23-34(L1)、50-56(L2)和89-97(L3)附近，和重链可变区中31-35B(H1)、50-65(H2)和95-102(H3)附近的氨基酸残基(Kabat等人，Sequences of Proteins of Immunological Interest，5th Ed.Public Health Service，National Institutes of Health，Bethesda，MD.(1991))；和/或来自“高变环”(例如，轻链可变区中26-32(LI)、50-52(L2)和91-96(L3)，和重链可变区中26-32(H1)、53-55(H2)和96-101(H3)附近的氨基酸残基(Chothia和Lesk J.Mol.Biol.196：901-917(1987))。
在本文中，术语“同一性”用于描述相对于参考序列的氨基酸序列或核酸序列时，采用通过常规的方法进行确定两个氨基酸序列或核酸序列之间的相同氨基酸或核苷酸的百分比，例如参见，Ausubel等，编著(1995)，Current Protocols in Molecular Biology，第19章(Greene Publishing and Wiley-Interscience，New York)；和ALIGN程序(Dayhoff(1978)，Atlas of Protein Sequence and Structure 5：Suppl.3(National Biomedical Research Foundation，Washington，D.C.)。关于比对序列和测定序列同一性有很多算法，包括，Needleman等(1970)J.Mol.Biol.48：443的同源性比对算法；Smith等(1981)Adv.Appl.Math.2：482的局部同源性算法；Pearson等(1988)Proc.Natl.Acad.Sci.85：2444的相似性搜索方法；Smith-Waterman算法(Meth.Mol.Biol.70：173-187(1997)；和BLASTP，BLASTN，和BLASTX算法(参见Altschul等(1990)J.Mol.Biol.215：403-410)。利用这些算法的计算机程序也是可获得的，并且包括但不限于：ALIGN或Megalign(DNASTAR)软件，或者WU-BLAST-2(Altschul等，Meth.Enzym.，266：460-480(1996))；或者GAP，BESTFIT，BLAST Altschul等，上文，FASTA，和TFASTA，在Genetics Computing Group(GCG)包，8版，Madison，Wisconsin，USA中可获得；和Intelligenetics，Mountain View，California提供的PC/Gene程序中的CLUSTAL。
在不实质性影响抗体活性(保留至少95％的活性)的前提下，本领域技术人员可以对本发明的序列替换、添加和/或缺失一个或更多个(例如1、2、3、4、5、6、7、8、9或10个或更多个)氨基酸，以获得所述抗体或其功能性片段之序列的变体。它们都被视为包括在本发明保护的范围内。如在可变区将具有类似性质的氨基酸进行替换。本发明所述变体序列可以与参比序列具有至少80％、85％、90％、95％、96％、97％、98％或99％的一致性(或同源性)。本发明所述的序列一致性可以使用序列分析软件测量。例如使用缺省参数的计算机程序BLAST，尤其是BLASTP或TBLASTN。本发明述及的氨基酸序列均按照N端至C端的方式示出。
如前所述，本发明的单抗可以是全长抗体或可仅包含其功能性片段(例如，Fab、F(ab’)2或scFv片段)，或可以被修饰以影响功能。本发明包括具有修饰的糖基化模式的抗CD16A抗体。在一些应用中，进行修饰以除去不期望的糖基化位点可以是有用的，或在寡糖链上不存在岩藻糖部分以例如增强抗体依赖性细胞毒性(ADCC)功能的抗体。在另一些应用中，可进行半乳糖基化修饰以改变补体依赖性细胞毒性(CDC)。
在本文中，所述“全长抗体”是由两条相同的轻链和两条相同的重链通过链间二硫键连接而成的四肽链结构，如免疫球蛋白G(IgG)、免疫球蛋白A(IgA)、免疫球蛋白M(IgM)、免疫球蛋白D(IgD)或免疫球蛋白E(IgE)。
本文所使用的术语“功能性片段”尤其是指抗体片段如CDR移植抗体、Fab、Fab’、F(ab’)2、Fv或scFv，纳米抗体、或者通过化学修饰或通过掺入脂质体中应能够增加半寿期的任何片段，所述化学修饰例如添加聚(亚烷基)二醇，如聚乙二醇(“聚乙二醇化，PEG化”)(被称为Fv-PEG、scFv-PEG、Fab-PEG、F(ab’)2-PEG或Fab’-PEG的聚乙二醇化片段)(“PEG”为聚乙二醇)，所述片段具有CD16A结合活性。优选地，所述功能性片段将由其来源抗体的重链可变区或轻链可变区的部分序列构成或者包含它们，所述部分序列足以保留与其来源抗体相同的结合特异性和充分的亲和力，对于CD16A，优选至少等于其来源抗体亲和力的1/100，在更优选方式中至少等于1/10。这种功能片段将包含最少3个氨基酸，优选其来源的抗体序列的5、10、15、25、50和100个连续氨基酸。
在本发明中，在未作相反说明的情况下，使用的术语“抗原结合片段”通常是指抗原结合性抗体片段，可以包括完整抗体的一部分，一般是抗原结合区或可变区，示例性的，如包括CDR移植抗体、Fab、Fab’、F(ab’)2、Fv或scFv，纳米抗体等。
在本文中，术语“CDR移植抗体”是指将一个物种单抗的CDR移植至另一物种抗体可变区。例如，可将鼠源单抗的CDR移植至人源抗体可变区，以便替代人源抗体CDR，使人源抗体获得鼠源单抗的抗原结合特异性，同时减少其异源性。
在本文中，术语“Fab抗体”或“Fab”通常是指仅含Fab分子的抗体，其由重链的VH和CH1以及完整的轻链构成，轻链和重链之间通过一个二硫键连接。
在本文中，术语“纳米抗体”(单域抗体或VHH抗体)，其最初被描述为“重链抗体”(即“缺乏轻链的抗体”)的抗原结 合免疫球蛋白(可变)域(Hamers-Casterman C,AtarhouchT,Muyldermans S,Robinson G,Hamers C,Songa EB,Bendahman N,Hamers R.:“Naturallyoccurring antibodies devoid of light chains”；Nature 363,446-448(1993))，只包含重链可变区(VH)和常规的CH2与CH3区，其通过重链可变区与抗原特异性结合。
在本文中，术语“Fv抗体”通常是指仅由轻链可变区(VL)和重链可变区(VH)通过非共价键连接而成的抗体，是抗体分了保留完整抗原结合部位的最小功能片段。
在本文中，术语“单链抗体”或“scFv”是由抗体重链可变区和轻链可变区通过短肽连接而成的片段。
在本文中，“knob into hole结构”为在抗体重链恒定区的CH3区形成钮(Knob)扣(hole)突变，便于重链咬合，形成异二聚体，例如，本申请中，通过突变人IgG1重链恒定区CH3结构域中氨基酸(一条链中为T366S、L368A、Y407V、Y349C突变，即“hole”；另一链中为T366W、S354C突变，即“knob”)实现。其中，此处的氨基酸编号为根据Kabat编号系统进行编号，例如，所述“T366S”是指按照Kabat编号系统编号第366位的T氨基酸被S氨基酸替代。
本发明所涉及的氨基酸或核酸序列详见表1。
表1：







以下将通过实施例对本发明进行详细描述。实施例或测试例中，未注明具体条件的实验方法的，均按照常规条件进行。
下面将结合实施例对本发明的方案进行解释。本领域技术人员将会理解，下面的实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体技术或条件的，按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者，均为可以通过市购获得的常规产品。
实施例1构建过表达人和食蟹猴CD16A的CHO-K1细胞
在T150培养瓶内将HEK293T细胞铺板，用DMEM完全培养基培养。培养过夜后，取无内毒素的psPAX2，pMD2.G和pCDH-CMV-FCGR3A-IRES-puro(pCDH-CMV-MCS-IRES-puro载体多克隆位点之间插入有人CD16A蛋白(SEQ ID NO:37)的编码序列(SEQ ID NO:57))或者食蟹猴蛋白(SEQ ID NO:38)的编码序列(SEQ ID NO:58)载体按照7：3：10的比例加入到1.5mL Opti-MEM(Gibco，货号31985070)培养基中，再加入100μL P3000转染试剂。取100μL Lipofectamine 3000(thermo，货号L3000008)转染试剂加入到1.5mL Opti-MEM培养基中，充分混匀。将DNA稀释液和脂质体稀释液按体积比1：1混匀，室温孵育5-10min后加入到293T细胞中，培养48小时后收获病毒上清。将病毒上清于4℃，2000g离心10min，取上清，用0.45μm滤器过滤后加入PEG8000溶液(上海生工)，充分混匀，4℃放置过夜，然后于2200g离心90min，离心管底部有白色沉淀，用无菌PBS缓冲液重悬病毒。
向DME/F12培养基中加入polybrene(sigma，TR-1003)(终浓度8μg/mL)，混匀后再加入适量病毒溶液。取2E5的CHO-K1细胞于24孔板中，加入带有病毒的培养基，放入培养箱8小时后更换新鲜培养基。48小时通过流式细胞仪检测CHO-K1细胞表面的CD16A表达水平，出现阳性群细胞后再进行有限稀释，即把细胞消化后稀释密度为每毫升4个细胞，再接种于96孔平底板中，每孔加入200μl，培养2周待细胞明显成为单个细胞团后，再通过流式细胞术检测每个克隆细胞表面CD16A的表达水平，全阳性细胞即为满足需要的过表达人CD16A或者食蟹猴CD16的CHO-K1细胞。
实施例2抗人CD16A杂交瘤单克隆抗体的制备
本发明中，抗人CD16A单克隆抗体通过免疫小鼠产生。实验用C57BL/6小鼠，雌性，6周龄(江苏集萃药康生物科技有限公司)，免疫抗原为人CD16A胞外段蛋白(ACRO，CDA-H5220)，首次免疫用弗氏完全佐剂(Sigma，F5881)与抗原混合乳化后腹腔免疫，每只小鼠腹腔注射100μg(请贵方补充黄色高亮标记的免疫方式)，后续免疫用Ribi佐剂系统(Sigma，S6322)与抗原混合后腹腔免疫，其中，首免后每2周免疫一次，共免疫3次。取免疫后的小鼠血清进行抗体滴度ELISA检测，其操作方法为本领域常规方法。
根据抗体滴度的检测结果，选择血清中抗体滴度高小鼠进行脾细胞融合，融合前72小时冲刺免疫所选小鼠，使用Ribi佐剂系统和上述抗原的混合物腹腔注射。采用优化的PEG介导的融合步骤将脾淋巴细胞与骨髓瘤细胞Sp2/0细胞(ATCC，CRL-8287)进行融合得到杂交瘤细胞。融合好的杂交瘤细胞用HAT完全培养基(含20％FBS、1×HAT和1×OPI的RPMI-1640培养基)重悬，分装于96孔细胞培养板中，于37℃、5％CO2孵育。融合后的第5天加入HAT完全培养基，50μL/孔。融合后第7天～8天，根据细胞生长密度，全换液，培养基为HT完全培养基(含20％FBS、1×HT和1×OPI的RPMI-1640培养基)，200μL/孔。
融合后第10-11天，根据细胞生长密度，进行流式细胞术结合检测。阳性孔换液，并根据细胞密度及时扩大至24孔板中。移入24孔板的细胞株经过复测后进行保种和第一次亚克隆。第一次亚克隆筛选为阳性的进行保种，并进行第二次亚克隆。第二次亚克隆为阳性的进行保种和蛋白表达。其中，亚克隆和保种操作均为本领域常规技术操作，通过无血清细胞培养法进一步制备抗体，通过protein G亲和层析纯化鼠源抗体，用于后续功能活性检测。
实施例3鼠源CD16A抗体ELISA结合实验
ELISA实验用于检测实施例1获得的鼠源CD16A抗体m40F5的结合特性。将人CD16A158F(ACRO biosystems，CDA-H5220)，人CD16A158V(ACRO biosystems，CD8-H52H4)，食蟹猴CD16(ACRO biosystems，FC6-C52H9)，人CD16BNA1(ACRO biosystems，CDB-H5227)，人CD16BNA2(ACRO biosystems，CDB-H5222)和人CD16BSH(义翘神州，11046-H08H2)分别用包被缓冲液(35mM NaHCO3，15mM Na2CO3,pH 9.6)稀释至2μg/mL，向酶联板中每孔加入100μL，4℃过夜。之后用PBST清洗3遍(0.05％Tween 20-PBS，pH7.2)。向板中加入300μL封闭缓冲液(1％BSA,0.05％Tween20-PBS,pH 7.2)，室温静置2h。再用PBST清洗3遍。每孔加入鼠源抗体m40F5或者对照抗体LS21(WO2006/125668EN)，室温孵育1小时。再用PBST清洗3遍。每孔加入100μL用封闭缓冲液稀释的HRP-羊抗鼠IgG二抗(boster，货号BA1051)，室温孵育1小时。用PBST清洗3遍，每孔加入TMB，室温避光反应2-5分钟，每孔再用2M硫酸终止反应，最后用酶标仪读取OD450数值。其中，图1A表明本发明的鼠源m40F5抗体可以结合人CD16A158F，图1B表明本发明的鼠源m40F5抗体也可以结合人CD16A158V，图1C表明本发明的鼠源m40F5可以结合食蟹猴CD16，图1D表明本发明的鼠源m40F5不结合人CD16BNA1，图1E表明本发明的鼠源40F5不结合人CD16BNA2，图1F表明本发明的鼠源40F5不结合人CD16BSH。
实施例4鼠源CD16A抗体流式细胞术结合实验
用PBS将实施例1获得的过表达人CD16A的CHO-K1细胞或者过表达食蟹猴CD16的CHO-K1细胞稀释为2×106/mL，以100μL/管的体积加于1.5mL EP管中，向其中加入10μL/管山羊血清，于4℃封闭30min。加入梯度浓度(5倍稀释，终浓度最高10μg/mL)的CD16A抗体以及对照抗体mIgG，于4℃孵育30min。向EP管中加入1mL PBS，于4℃，3500rpm×5min离心，弃尽上清，再用PBS洗一遍。离心后弃尽上清，用100μL/管PBS重悬细胞，向其中加入0.1μL/管Alexa 647标记的山羊抗小鼠抗体二抗(Invitrogen)，4℃避光孵育30min。用PBS洗两遍，离心后弃尽上清。用200μL/管PBS重悬细胞，用流式细胞仪进行检测。图2A和2B结果表明鼠源m40F5抗体可以结合过表达人CD16A和过表达食蟹猴CD16的CHO-K1细胞，说明鼠源CD16A抗体可以结合细胞表面的CD16A蛋白。
实施例5杂交瘤细胞测序
将上述实施例筛选到的m40F5抗体候选杂交瘤细胞总数量培养到106，800rpm离心10分钟收集细胞，并以Trizol试剂盒(Invitrogen)提取总RNA；以总RNA为模板，逆转录合成cDNA文库(Invitrogen)，又以cDNA为模板PCR扩增杂交瘤细胞的所对应的m40F5抗体可变区核酸序列。PCR扩增反应中所使用的引物序列与抗体可变区第一框架区或信号肽区和恒定区互补(具体序列选择参考Larrick，J.W.，et al.，(1990)Scand.J.Immunol.，32，121 128和Coloma，J.J.et al.，(1991)BioTechniques，11，152 156)。PCR扩增在50μL反应体系中进行，分别加入cDNA 2μL，10×PCR缓冲液5μL，上游及下游引物2μL(5μM)，dNTP 2μL，Taq酶1μL(Takara，Ex Taq)，H2O 38μL；95℃预变性5min，进入温度循环，进行PCR扩增。反应条件为：94℃变性30S，58℃退火45S，72℃延伸50S，共32个循环，然后于72℃延伸7min。将扩增产物进行测序后，得到鼠单抗m40F5的重链可变区(SEQ ID NO:23)和轻链可变区(SEQ ID NO:24)序列。
实施例6抗人CD16A单克隆抗体的人源化
6.1 CD16A单克隆抗体可变区框架的选择与回复突变
在实施例5获的基础上，通过比对IMGT人类抗体重轻链可变区种系基因数据库和MOE软件，分别挑选与鼠源单克隆抗体m40F5同源性高的重链或轻链可变区种系基因作为模板，将鼠源单克隆抗体的CDR分别移植到相应的人源模板中，形成次序为FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4的可变区序列。其中氨基酸残基由Kabat编号系统确定并注释。
为了保持CDR区构象，对于VL和VH结合界面上的残基，靠近CDR并且包埋于蛋白内部的残基，与CDR有直接相互作用的残基进行回复突变，以保证可变区的活性不会受影响。
6.2 CD16A人源化抗体的表达
对上述CD16A单克隆抗体可变区框架进行选择与回复突变后，获得的人源化CD16A抗体h40F5的重链可变区序列如SEQ ID NO:25所示，轻链可变区序列如SEQ ID NO:26所示。将带有编码人源化抗体重链的核苷酸序列(SEQ ID NO:39)和编码人源化抗体轻链的核苷酸序列(SEQ ID NO:40)通过分子生物学技术分别重组到pTT5质粒上。
用上述携带有人源化抗人CD16A抗体h40F5轻链和重链的pTT5载体瞬时转染ExpiCHO-S细胞(Gibco，货号A29127)来制备CD16A抗体。转染前一天，将ExpiCHO-S细胞调整细胞密度为(3～4)×106/mL，37℃，8％CO2，120rpm摇动培养过夜。转染当天，细胞生长到7×106～1×107/mL，存活率大于95％时准备转染，使用新鲜预热的ExpiCHO培养基(Gibco， 货号A2910002)将细胞稀释到6×106/mL，将上述携带有人源化抗人CD16A抗体h40F5轻链和重链的pTT5质粒和ExpiFectamine CHO转染试剂(Gibco，货号A29129)以2：1摩尔比转染到ExpiCHO-S细胞中，于37℃，8％CO2，120rpm摇动培养。转染后18-22h，将ExpiFectamine CHO Enhancer和ExpiCHO Feed混匀后立即加入转染后细胞，混匀，于32℃，5％CO2，120rpm摇动培养。转染后第5天，向细胞中再补加8mL ExpiCHO Feed，混匀后继续培养。每日观察细胞数和细胞活率变化，待细胞活率下降至80％以下或培养10～14天后离心收获细胞。表达的上清用0.22μm滤膜过滤，利用Mabselect prism A亲和层析柱(GE公司，货号17549854)从表达上清中捕获带有Fc结构域的抗体，用pH7.2的磷酸盐缓冲液平衡层析柱后，上清过亲和层析柱，用洗脱缓冲液(100mM柠檬酸，pH2.7)洗脱，最后用PBS缓冲液浓缩置换，纯化后的抗体通过SDS-PAGE鉴定纯度在95％以上，最终获得了人源化h40F5抗体(重链如SEQ ID NO:35所示，轻链如SEQ ID NO:36所示)。
6.3人源化抗体h40F5亲和力验证
用BIACORE测试人源化h40F5抗体与人CD16A抗原、人CD16B和猴CD16抗原的亲和力，得到的结果如表2所示，获得的人源化抗体与CD16A抗原具有较好的亲和力。
表2
实施例7人源化抗体h40F5的ELISA结合实验
ELISA实验用于检测人源化抗体h40F5的结合特性，其中，以野生型人源IgG1抗体为对照。将人CD16A158F(ACRO biosystems，CDA-H5220)，人CD16A158V(ACRO biosystems，CD8-H52H4)，食蟹猴CD16(ACRO biosystems，FC6-C52H9)，人CD16BNA1(ACRO biosystems，CDB-H5227)，人CD16BNA2(ACRO biosystems，CDB-H5222)和人CD16BSH(义翘神州，11046-H08H2)用包被缓冲液(35mM NaHCO3，15mM Na2CO3，pH 9.6)稀释至2μg/mL，向酶联板中每孔加入100μL，4℃过夜。之后用PBST清洗3遍(0.05％Tween 20-PBS，pH7.2)。向板中加入300μL封闭缓冲液(1％BSA,0.05％Tween20-PBS,pH 7.2)，室温静置2h。再用PBST清洗3遍。每孔加入梯度浓度的人源化抗人CD16A抗体h40F5或人源IgG1抗体，室温孵育1小时。再用PBST清洗3遍。每孔加入100μL用封闭缓冲液稀释的HRP-山羊抗人IgG二抗(Jackson ImmunoResearch，109-036-170))，室温孵育1小时。用PBST清洗3遍，每孔加入TMB，室温避光反应2～5分钟，每孔再用2M硫酸终止反应，最后用酶标仪读取OD450数值。图3A表明本发明的人源化h40F5抗体可以结合人CD16A158F，图3B表明本发明的人源化h40F5抗体也可以结合人CD16A158V，图3C表明本发明的人源化h40F5可以结合食蟹猴CD16，图3D表明本发明的人源化h40F5不结合人CD16BNA1，图3E表明本发明的人源化h40F5不结合人CD16BNA2，图3F表明本发明的人源化h40F5不结合人CD16BSH。
实施例8 CD16A×BCMA的双特异性抗体的制备及结合活性和细胞杀伤能力检测
基于实施例1-7的实验结果，发明人设计了一种双特异性抗体CD16A×BCMA，并对该双特异性抗体的结合活性和细胞杀伤能力进行检测。
8.1 CD16A×BCMA的双特异性抗体的设计及制备
该抗体含有两个单价单元，其中一个单价单元为抗CD16A scFv-Fc形式，其重链可变区和轻链可变区氨基酸序列来自本发明实施例6获得的人源化抗体h40F5的序列，另一个单价单元为抗BCMA的scFv-Fc形式(序列来自US009273141B2)，该双特异性抗体命名为CD16A×BCMA。该双特异性抗体含有两条多肽链，分别是：含有CD16A单链抗体scFv(SEQ ID NO：41)的重链，含有BCMA单链抗体scFv(SEQ ID NO：42)的重链，其中两条链的重链恒定区来自于人源抗体IgG1。由于该分子有特殊的非对称结构，为了减少同源二聚体的产生，所以在两条链的恒定区引入了不同的氨基酸突变。同时为了防止由Fcγ受体引起的交联活化，在重链恒定区也引入了(L234A/L235A)突变。
双特异性抗体的制备方法参考实施例6.2所述方法，并结合质粒配比(1：1或其他比例)并经过一步亲和纯化制备所述双特异性抗体，其中，所述双特异性抗体CD16A×BCMA的相关序列如表3所示。
表3
8.2 CD16A×BCMA双特异性抗体与抗原的结合活性测定(ELISA)
将人BCMA(ACRO biosystems，BCA-H522y)或人CD16A抗原(ACRO biosystems，CDD-H52W1)用包被缓冲液(35mM NaHCO3，15mM Na2CO3，pH 9.6)稀释至2μg/mL，向酶联板中每孔加入100μL，于4℃过夜。之后用PBST清洗3遍(0.05％Tween 20-PBS，pH7.2)。向板中加入300μL封闭缓冲液(1％BSA，0.05％Tween20-PBS，pH 7.2)，室温静置2h。再用PBST清洗3遍。每孔加入相应双特异性抗体或对照抗体hIgG1，室温孵育1小时。再用PBST清洗沉淀3遍。每孔加入100μL用封闭缓冲液稀释的HRP-山羊抗人IgG二抗(Jackson ImmunoResearch，109-036-170)，于室温孵育1小时。用PBST清洗3遍，每孔加入TMB，室温避光反应2～5分钟，每孔再用2M硫酸终止反应，最后用酶标仪读取OD450数值。图4A和4B显示本发明CD16A×BCMA可以结合CD16A和BCMA这两种抗原。
8.3细胞杀伤实验
将多发性骨髓瘤NCI-H929细胞标记CellTrace Violet(thermo，C34557)，调整细胞密度为1×105/mL。PBMC调整细胞密度1×106/mL，将PBMC和标记后的NCI-H929细胞以1：1混合后加入到96孔圆底板中，再加入梯度浓度的上述双特异性抗体，混合均匀。于37℃孵育24h后过200目尼龙网转入流式管，加入7AAD后10min进行检测，利用CTV+7AAD+细胞比例表征杀伤效率。图5结果显示随着CD16A×BCMA双特异性抗体浓度增加，PBMC对NCI-H929多发性骨髓瘤细胞的杀伤效率逐渐增加。
实施例9 CD16A×B7H6的双特异性抗体的制备及结合活性和细胞杀伤能力检测
基于实施例1-6的实验结果，发明人设计了一种双特异性抗体CD16A×B7H6，并对该双特异性抗体的结合活性和细胞杀伤能力进行检测。
9.1 CD16A×B7H6的双特异性抗体的设计及制备
该抗体含有两个单价单元，其中一个单价单元为抗CD16A scFv-Fc形式，CD16A scFv中的轻链可变区和重链可变区来自本发明实施例6人源化后序列，另一个单价单元为抗B7H6scFv-Fc形式(B7H6scFv序列来自CN114395045A)，这个双特异性抗体命名为CD16A×B7H6。该双特异性抗体含有两条多肽链，分别是：含有CD16A单链抗体scFv(SEQ ID NO：41)的重链，含有B7H6单链抗体scFv(SEQ ID NO：43)的重链。由于该分子有特殊的非对称结构，为了减少同源二聚体的产生，所以在两条链的恒定区引入了不同的氨基酸突变。同时为了防止由Fcγ受体引起的交联活化，在重链恒定区也引入了(L234A/L235A)突变。
CD16A×B7H6的双特异性抗体的制备方法参考实施例6.2，并结合质粒配比(1：1或其他比例)并经过一步亲和纯化制备CD16A×B7H6双特异性抗体，所述双特异性抗体CD16A×B7H6的相关序列如表4所示。
表4
9.2双特异性抗体与抗原的结合活性测定(ELISA)
将人B7H6(ACRO biosystems，B76-H52H8)或人CD16A抗原(ACRO biosystems，货号CDA-H5220)用包被缓冲液(35mM NaHCO3，15mM Na2CO3，pH 9.6)稀释至2μg/mL，向酶联板中每孔加入100μL，于4℃过夜。之后用PBST清洗3遍(0.05％Tween 20-PBS，pH7.2)。向板中加入300μL封闭缓冲液(1％BSA，0.05％Tween20-PBS，pH 7.2)，室温静置2h。再用PBST清洗3遍。每孔加入相应双特异性抗体或对照抗体hIgG，室温孵育1小时。再用PBST清洗3遍。每孔加入100μL用封闭缓冲液稀释的HRP-山羊抗人IgG二抗(Jackson ImmunoResearch，109-036-170)，于室温孵育1小时。孵育结束后，用PBST清洗沉淀3遍，每孔加入TMB，室温避光反应2～5分钟，每孔再用2M硫酸终止反应，最后用酶标仪读取OD450数值。图6A和6B显示，本发明的双特异性抗体CD16A×B7H6可以有效结合CD16A和B7H6这两种抗原。
9.3细胞杀伤实验
将结直肠癌HCT-15细胞消化后计数，调整细胞密度为2×105/mL。打开RTCA仪器(安捷伦)，选择仪器类型DP，选择实验模式，填写细胞信息和药物信息。进入schedule设置实验步骤，将板子加入50μL新鲜培养基(89％RPMI 1640培养基+10％胎牛血清+1％青链霉素)后放入仪器中，关好，点击第一步开始。完成Done后取出板子，加入100μL细胞悬液，室温静置15-30min防止边缘效应，放入仪器，点击开始。待生长到对数期后，暂停，加入50μL PBMC(4×106/mL)，并加入梯度浓度的双特异性抗体CD16A×B7H6或对照抗体hIgG，点击开始，一段时间后进行分析。图7结果显示，随着CD16A×B7H6双特异性抗体浓度增加，PBMC对结直肠癌HCT-15细胞的杀伤效率逐渐增加，说明CD16A×B7H6可以很好地促进PBMC特异性地杀伤B7H6+的肿瘤细胞。
在本说明书的描述中，参考术语“一个实施例”、“一些实施例”、“示例”、“具体示例”、或“一些示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中，对上述术语的示意性表述不必须针对的是相同的实施例或示例。而且，描述的具体特征、结构、材料或者特点可以在任一个或多个实施例或示例中以合适的方式结合。此外，在不相互矛盾的情况下，本领域的技术人员可以将本说明书中描述的不同实施例或示例以及不同实施例或示例的特征进行结合和组合。
尽管上面已经示出和描述了本发明的实施例，可以理解的是，上述实施例是示例性的，不能理解为对本发明的限制，本领域的普通技术人员在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。

Claims (79)

  1. 一种抗体或抗原结合片段，其特征在于，包括：
    分别如SEQ ID NO:1、2和3或者与SEQ ID NO:1、2和3具有至少95％同一性的氨基酸序列所示的重链可变区CDR1、CDR2、CDR3序列；和/或
    分别如SEQ ID NO:4、5和6或者与4、5和6具有至少95％同一性的氨基酸序列所示的轻链可变区CDR1、CDR2、CDR3序列。
  2. 根据权利要求1所述的抗体或抗原结合片段，其特征在于，包括：
    如SEQ ID NO:1所示的重链可变区CDR1序列，如SEQ ID NO:2所示的重链可变区CDR2，如SEQ ID NO:3所示的重链可变区CDR3，SEQ ID NO:4所示的轻链可变区CDR1，SEQ ID NO:5所示的轻链可变区CDR2，SEQ ID NO:6所示的轻链可变区CDR3。
  3. 根据权利要求2所述的抗体或抗原结合片段，其特征在于，包括：重链FR区和轻链FR区中的至少之一。
  4. 根据权利要求3所述的或抗原结合片段，其特征在于，所述重链FR区和轻链FR区的至少之一的至少一部分来自于人源抗体、灵长目源抗体和鼠源抗体或其突变体中的至少之一。
  5. 根据权利要求4所述的抗体或抗原结合片段，其特征在于，包括：
    分别如SEQ ID NO:7～10所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；或
    分别如SEQ ID NO:15～18所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一。
  6. 根据权利要求4所述的抗体或抗原结合片段，其特征在于，包括：
    分别如SEQ ID NO:11～14所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一；或
    分别如SEQ ID NO:19～22所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一。
  7. 根据权利要求5～6任一项所述的抗体或其抗原结合片段，其特征在于，包括：分别如SEQ ID NO:7～10所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；分别如SEQ ID NO:11～14所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一；或者
    分别如SEQ ID NO:15～18所示的重链框架区HFR1、HFR2、HFR3和HFR4序列中的至少之一；分别如SEQ ID NO:19～22所示的轻链框架区LFR1、LFR2、LFR3和LFR4序列中的至少之一。
  8. 根据权利要求7所述的抗体或其抗原结合片段，其特征在于，包括：
    如SEQ ID NO:23或SEQ ID NO:25所示的重链可变区；和/或
    如SEQ ID NO:24或SEQ ID NO:26所示的轻链可变区。
  9. 根据权利要求8所述的抗体或其抗原结合片段，其特征在于，包括：
    1)如SEQ ID NO:23所示的重链可变区，和如SEQ ID NO:24所示的轻链可变区；或
    2)如SEQ ID NO:25所示的重链可变区，和如SEQ ID NO:26所示的轻链可变区。
  10. 根据权利要求1～9任一项所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段含有重链恒定区和轻链恒定区的至少之一，所述重链恒定区和轻链恒定区的至少之一的至少一部分来自于人源抗体、灵长目源抗体和鼠源抗体或其突变体中的至少之一。
  11. 根据权利要求10所述的抗体或抗原结合片段，其特征在于，所述轻链恒定区和重链恒定区均来自于鼠源IgG抗体或其突变体或人源IgG抗体或其突变体。
  12. 根据权利要求11所述的抗体或抗原结合片段，其特征在于，所述轻链恒定区和重链恒定区均来自于鼠源IgG1抗体或其突变体或人源IgG1抗体或其突变体。
  13. 根据权利要求12所述的抗体或抗原结合片段，其特征在于，所述抗体具有如SEQ ID NO:27或29所示氨基酸序列的重链恒定区和/或如SEQ ID NO:28或30所示氨基酸序列的轻链恒定区。
  14. 根据权利要求10所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段具有SEQ ID NO:31、33和35任一项所示氨基酸序列的重链和具有SEQ ID NO:32、34和36任一项所示氨基酸序列的轻链。
  15. 根据权利要求10所述的抗体或抗原结合片段，其特征在于，所述抗体或抗原结合片段具有SEQ ID NO:31所示氨基酸序列的重链和SEQ ID NO:32所示氨基酸序列的轻链；
    所述抗体或抗原结合片段具有SEQ ID NO:33所示氨基酸序列的重链和SEQ ID NO:34所示氨基酸序列的轻链；或
    所述抗体或抗原结合片段具有SEQ ID NO:35所示氨基酸序列的重链和SEQ ID NO:36所示氨基酸序列的轻链。
  16. 根据权利要求1所述的抗体或其抗原结合片段，其特征在于，所述抗体或抗原结合片段包括单抗或多抗。
  17. 根据权利要求16所述的抗体或其抗原结合片段，其特征在于，所述单抗包括全长抗体、Fv、单链抗体、Fab、单域抗体以及最小识别单位中的至少之一。
  18. 根据权利要求16所述的抗体或其抗原结合片段，其特征在于，所述抗体或其抗原结合片段能够结合SEQ ID NO:37和/或38所示的氨基酸序列。
  19. 一种双特异性结合分子，其特征在于，包括：
    第一结合区，所述第一结合区包含权利要求1～18任一项所述的抗体或抗原结合片段；和
    第二结合区，所述第二结合区具有BCMA或B7H6结合活性。
  20. 根据权利要求19所述的双特异性结合分子，其特征在于，所述双特异性结合分子包括对称双特异性结合分子或不对称双特异性结合分子。
  21. 根据权利要求19所述的双特异性结合分子，其特征在于，所述双特异性结合分子为非对称双特异性结合分子。
  22. 根据权利要求19所述的双特异性结合分子，其特征在于，所述抗体或抗原结合片段为抗CD16A单链抗体。
  23. 根据权利要求22所述的双特异性结合分子，其特征在于，所述第二结合区包括具有BCMA或B7H6结合活性的全长抗体、Fv、单链抗体、Fab、单域抗体以及最小识别单位中的至少之一。
  24. 根据权利要求23所述的双特异性结合分子，其特征在于，所述第二结合区包括抗BCMA单链抗体或抗B7H6单链抗体。
  25. 根据权利要求24所述的双特异性结合分子，其特征在于，所述抗CD16A单链抗体包括抗CD16A抗体轻链可变区和抗CD16A抗体重链可变区，所述抗CD16A抗体重链可变区具有SEQ ID NO:23或25所示的氨基酸序列，所述抗CD16A抗体轻链可变区具有如SEQ ID NO:24或26所示的氨基酸序列。
  26. 根据权利要求25所述的双特异性结合分子，其特征在于，所述抗CD16A单链抗体进一步包括连接肽1，其中，所述连接肽1的N端与所述抗CD16A抗体重链可变区的C端相连，所述连接肽1的C端与所述抗CD16A抗体轻链可变区的N端相连；或所述连接肽1的N端与所述抗CD16A抗体轻链可变区的C端相连，所述连接肽1的C端与所述抗CD16A抗体重链可变区的N端相连。
  27. 根据权利要求26所述的双特异性结合分子，其特征在于，所述抗BCMA单链抗体包括抗BCMA抗体轻链可变区和抗BCMA抗体重链可变区，所述抗BCMA抗体重链可变区具有SEQ ID NO:59所示的氨基酸序列，所述抗BCMA抗体轻链可变区具有如SEQ ID NO:60所示的氨基酸序列。
  28. 根据权利要求27所述的双特异性结合分子，其特征在于，所述抗BCMA单链抗体进一步包括连接肽2，其中，所述连接肽2的N端与所述抗BCMA抗体重链可变区的C端相连，所述连接肽2的C端与所述抗BCMA抗体轻链可变区的N端相连；或所述连接肽2的N端与所述抗BCMA抗体轻链可变区的C端相连，所述连接肽2的C端与所述抗BCMA抗体重链可变区的N端相连。
  29. 根据权利要求28所述的双特异性结合分子，其特征在于，所述抗B7H6单链抗体包括抗B7H6抗体轻链可变区和抗B7H6抗体重链可变区，所述抗B7H6抗体重链可变区具有SEQ ID NO:61所示的氨基酸序列，所述抗B7H6抗体轻链可变区具有如SEQ ID NO:62所示的氨基酸序列。
  30. 根据权利要求29所述的双特异性结合分子，其特征在于，所述抗B7H6单链抗体进一步包括连接肽3，其中，所述连接肽3的N端与所述抗B7H6抗体重链可变区的C端相连，所述连接肽3的C端与所述抗B7H6抗体轻链可变区的N端相连；或所述连接肽3的N端与所述抗B7H6抗体轻链可变区的C端相连，所述连接肽3的C端与所述抗B7H6抗体重链可变区的N端相连。
  31. 根据权利要求30所述的双特异性结合分子，其特征在于，所述连接肽1、连接肽2和连接肽3中的至少之一具有氨基酸序列(GGGGS)n，其中n为大于或等于1的整数。
  32. 根据权利要求31所述的双特异性结合分子，其特征在于，n为1、2、3、4、5、6、7、8、9或10。
  33. 根据权利要求31所述的双特异性结合分子，其特征在于，所述连接肽1、连接肽2和连接肽3中的至少之一具有SEQ ID NO:44所示的氨基酸序列。
  34. 根据权利要求22所述的双特异性结合分子，其特征在于，所述抗CD16A单链抗体具有如SEQ ID NO:41所示的氨基酸序列。
  35. 根据权利要求24所述的双特异性结合分子，其特征在于，所述抗BCMA单链抗体具有如SEQ ID NO:42所示的氨基酸序列。
  36. 根据权利要求24所述的双特异性结合分子，其特征在于，所述抗B7H6单链抗体具有如SEQ ID NO:43所示的 氨基酸序列。
  37. 根据权利要求19所述的双特异性结合分子，其特征在于，所述第一抗原结合区进一步包括第一Fc肽段，所述第一Fc肽段的N端与所述抗体或抗原结合片段的C端相连。
  38. 根据权利要求37所述的双特异性结合分子，其特征在于，所述第二抗原结合区进一步包括第二Fc肽段，所述第二Fc肽段的N端与所述抗BCMA单链抗体或所述抗B7H6单链抗体的C端相连。
  39. 根据权利要求38所述的双特异性结合分子，其特征在于，所述第一Fc肽段具有SEQ ID NO:45所示的氨基酸序列。
  40. 根据权利要求39所述的双特异性结合分子，其特征在于，所述第二Fc肽段具有SEQ ID NO:46所示的氨基酸序列。
  41. 根据权利要求40所述的双特异性结合分子，其特征在于，所述第一Fc肽段和所述第二Fc肽段通过knob-into-hole结构进行连接。
  42. 根据权利要求19所述的双特异性结合分子，其特征在于，所述第一抗原结合区具有SEQ ID NO:47所示的氨基酸序列，所述第二抗原结合区具有SEQ ID NO:48或49所示的氨基酸序列。
  43. 一种核酸分子，其特征在于，所述核酸分子编码权利要求1～18任一项所述的抗体或抗原结合片段或权利要求19～42任一项所述的双特异性结合分子。
  44. 一种表达载体，其特征在于，携带权利要求43所述的核酸分子。
  45. 一种重组细胞，其特征在于，携带权利要求43所述的核酸分子、权利要求44所述的表达载体或能够表达权利要求1～18任一项所述的抗体或抗原结合片段或权利要求19～42任一项所述的双特异性结合分子。
  46. 根据权利要求45所述的重组细胞，其特征在于，所述重组细胞是通过将权利要求44所述的表达载体导入至宿主细胞中而获得的。
  47. 根据权利要求46所述的重组细胞，其特征在于，所述重组细胞为真核细胞。
  48. 根据权利要求46所述的重组细胞，其特征在于，所述重组细胞为哺乳动物细胞。
  49. 一种组合物，其特征在于，包括权利要求1～18任一项所述的抗体或抗原结合片段、权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞。
  50. 一种药物，其特征在于，包括权利要求1～18任一项所述的抗体或抗原结合片段、权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞或权利要求49所述的组合物。
  51. 一种试剂盒，其特征在于，所述试剂盒含有权利要求1～18任一项所述的抗体或抗原结合片段、权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞。
  52. 权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞或权利要求49所述的组合物在制备药物中的用途，所述药物用于预防和/或治疗CD16A介导的相关疾病。
  53. 根据权利要求52所述的用途，其特征在于，所述CD16A介导的相关疾病包括自身免疫性疾病。
  54. 根据权利要求52所述的用途，其特征在于，所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
  55. 权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞或权利要求49所述的组合物在制备药物中的用途，所述药物用于预防和/或治疗CD16A和BCMA，或者CD16A和B7H6介导的相关疾病。
  56. 根据权利要求55所述的用途，其特征在于，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
  57. 根据权利要求55所述的用途，其特征在于，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、 横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
  58. 权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞在制备试剂盒中的用途，所述试剂盒用于检测CD16A。
  59. 权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞在制备试剂盒中的用途，所述试剂盒用于检测CD16A和/或BCMA，或者，CD16A和/或B7H6。
  60. 权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞、权利要求49所述的组合物或权利要求50所述的药物在预防和/或治疗CD16A介导的相关疾病的用途。
  61. 根据权利要求60所述的用途，其特征在于，所述CD16A介导的相关疾病包括自身免疫性疾病。
  62. 根据权利要求61所述的用途，其特征在于，所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
  63. 权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞、权利要求49所述的组合物或权利要求50所述的药物在预防和/或治疗CD16A和BCMA，或者CD16A和B7H6介导的相关疾病的用途。
  64. 根据权利要求63所述的用途，其特征在于，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
  65. 根据权利要求64所述的用途，其特征在于，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
  66. 一种预防和/或治疗CD16A介导的相关疾病的方法，其特征在于，给予患者药学上可接受剂量的权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞、权利要求49所述的组合物或权利要求50所述的药物。
  67. 一种诊断CD16A介导的相关疾病的方法，其特征在于，包括使用权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞中的至少之一对待测样品中的CD16A进行检测，基于所述CD16A的检测结果，确定所述待测样品中CD16A的含量。
  68. 根据权利要求67所述的方法，其特征在于，所述待测样品中CD16A的含量不低于患病的最低标准是待测样品来源于患有CD16A引起的相关疾病的患者的指示。
  69. 一种评估CD16A介导的相关疾病预后的方法，其特征在于，包括使用权利要求1～18任一项所述的抗体或抗原结合片段、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞中的至少之一对待测样品中的CD16A进行检测，确定所述待测样品中CD16A的含量，并基于所述CD16A的含量对CD16A引起的相关疾病的预后进行评估。
  70. 根据权利要求67或69所述的方法，其特征在于，所述待测样品包括下列中的至少之一：血液、唾液、汗液、组织、细胞、血液、血清、血浆、粪便和尿液。
  71. 根据权利要求66、67或69任一项所述的方法，其特征在于，所述CD16A介导的相关疾病包括自身免疫性疾病。
  72. 根据权利要求71所述的方法，其特征在于，所述自身免疫性疾病包括下列中的至少之一：系统性红斑狼疮、类风湿性关节炎、系统性血管炎、硬皮病、皮肌炎、自身免疫性溶血性贫血、甲状腺自身免疫病、溃疡性结肠炎、慢性淋巴细胞性甲状腺炎、甲状腺功能亢进、胰岛素依赖型糖尿病、重症肌无力、溃疡性结肠炎、恶性贫血伴慢性萎缩性胃炎、肺出血肾炎综合征、寻常天疱疮、类天疱疮、原发性胆汁性肝硬化、多发性脑脊髓硬化症和急性特发性多神经炎。
  73. 一种预防和/或治疗CD16A和BCMA，或者CD16A和B7H6介导的相关疾病的方法，其特征在于，给予患者药学上可接受剂量的权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体、权利要求45～48任一项所述的重组细胞、权利要求49所述的组合物或权利要求50所述的药物。
  74. 一种诊断CD16A和BCMA，或者CD16A和B7H6介导的相关疾病的方法，其特征在于，包括使用权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项 所述的重组细胞中的至少之一对待测样品中的CD16A和BCMA，或者，CD16A和B7H6进行检测，基于所述CD16A和BCMA，或者，CD16A和B7H6的检测结果，确定所述待测样品中CD16A和BCMA，或者，CD16A和B7H6的含量。
  75. 根据权利要求74所述的方法，其特征在于，所述待测样品中CD16A和BCMA，或者，CD16A和B7H6的含量不低于患病的最低标准是待测样品来源于患有CD16A和BCMA，或者，CD16A和B7H6引起的相关疾病的患者的指示。
  76. 一种评估CD16A和BCMA，或者，CD16A和B7H6介导的相关疾病预后的方法，其特征在于，包括使用权利要求19～42任一项所述的双特异性结合分子、权利要求43所述的核酸分子、权利要求44所述的表达载体或权利要求45～48任一项所述的重组细胞中的至少之一对待测样品中的CD16A和BCMA，或者，CD16A和B7H6进行检测，确定所述待测样品中CD16A和BCMA，或者，CD16A和B7H6的含量，并基于所述CD16A和BCMA，或者，CD16A和B7H6的含量对CD16A和BCMA，或者，CD16A和B7H6引起的相关疾病的预后进行评估。
  77. 根据权利要求74或76所述的方法，其特征在于，所述待测样品包括下列中的至少之一：血液、唾液、汗液、组织、细胞、血液、血清、血浆、粪便和尿液。
  78. 根据权利要求73、74或76任一项所述的方法，其特征在于，所述CD16A和BCMA，或者CD16A和B7H6介导的相关疾病包括癌症。
  79. 根据权利要求78所述的方法，其特征在于，所述癌症包括下列中的至少之一：血管瘤、胃癌、肝癌、肺癌、乳腺癌、结肠癌、鼻咽癌、膀胱癌、宫颈癌、前列腺癌、骨癌、皮肤癌、甲状腺癌、肾癌、食道癌、黑色素瘤、纤维肉瘤、横纹肌肉瘤、星形细胞瘤、神经母细胞瘤和神经胶质瘤。
PCT/CN2023/086262 2022-10-27 2023-04-04 抗cd16a的抗体及其应用 Ceased WO2024087515A1 (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2025524844A JP2026512563A (ja) 2022-10-27 2023-04-04 抗ｃｄ１６ａ抗体及びその使用
AU2023370296A AU2023370296A1 (en) 2022-10-27 2023-04-04 Anti-cd16a antibody and application thereof
KR1020257017243A KR20250084976A (ko) 2022-10-27 2023-04-04 항cd16a 항체 및 이의 적용
IL320488A IL320488A (en) 2022-10-27 2023-04-04 Anti-cd16a antibody and application thereof
EP23881112.9A EP4596581A4 (en) 2022-10-27 2023-04-04 Anti-CD16A Antibody and Its Use
US19/188,009 US20250297012A1 (en) 2022-10-27 2025-04-24 Anti-cd16a antibody and application thereof
MX2025004739A MX2025004739A (es) 2022-10-27 2025-04-24 Anticuerpo anti-cd16a y aplicacion del mismo
ZA2025/03670A ZA202503670B (en) 2022-10-27 2025-04-29 Anti-cd16a antibody and application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211327361.8 2022-10-27
CN202211327361.8A CN115960234B (zh) 2022-10-27 2022-10-27 抗cd16a的抗体及其应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US19/188,009 Continuation US20250297012A1 (en) 2022-10-27 2025-04-24 Anti-cd16a antibody and application thereof

Publications (1)

Publication Number Publication Date
WO2024087515A1 true WO2024087515A1 (zh) 2024-05-02

Family

ID=87359233

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/086262 Ceased WO2024087515A1 (zh) 2022-10-27 2023-04-04 抗cd16a的抗体及其应用

Country Status (10)

Country Link
US (1) US20250297012A1 (zh)
EP (1) EP4596581A4 (zh)
JP (1) JP2026512563A (zh)
KR (1) KR20250084976A (zh)
CN (1) CN115960234B (zh)
AU (1) AU2023370296A1 (zh)
IL (1) IL320488A (zh)
MX (1) MX2025004739A (zh)
WO (1) WO2024087515A1 (zh)
ZA (1) ZA202503670B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218645A1 (zh) * 2024-04-16 2025-10-23 深圳众格生物科技有限公司 抗cd16a抗体及其用途
CN118221818B (zh) * 2024-04-29 2025-01-24 四川大学 一种抗cd16a的纳米抗体及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125668A2 (en) 2005-05-26 2006-11-30 Affimed Therapeutics Ag Anti-cd16 binding molecules
US9273141B2 (en) 2011-05-27 2016-03-01 Glaxo Group Limited B cell maturation antigen (BCMA) binding proteins
CN110382539A (zh) * 2017-02-28 2019-10-25 阿菲姆德股份有限公司 用于cd16a定向的nk细胞结合的串联双抗体
CN110959015A (zh) * 2017-07-12 2020-04-03 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
CN112789291A (zh) * 2018-08-08 2021-05-11 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN113490687A (zh) * 2018-12-26 2021-10-08 西利欧发展公司 抗ctla4抗体和其使用方法
CN114395044A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 重组抗体及其应用
CN114395045A (zh) 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 B7h6抗体及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483472T1 (de) * 2002-05-30 2010-10-15 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125668A2 (en) 2005-05-26 2006-11-30 Affimed Therapeutics Ag Anti-cd16 binding molecules
US9273141B2 (en) 2011-05-27 2016-03-01 Glaxo Group Limited B cell maturation antigen (BCMA) binding proteins
CN110382539A (zh) * 2017-02-28 2019-10-25 阿菲姆德股份有限公司 用于cd16a定向的nk细胞结合的串联双抗体
CN110959015A (zh) * 2017-07-12 2020-04-03 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
CN112789291A (zh) * 2018-08-08 2021-05-11 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CN113490687A (zh) * 2018-12-26 2021-10-08 西利欧发展公司 抗ctla4抗体和其使用方法
CN114395044A (zh) * 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 重组抗体及其应用
CN114395045A (zh) 2021-12-07 2022-04-26 合肥天港免疫药物有限公司 B7h6抗体及其应用

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1995, GREENE PUBLISHING AND WILEY-INTERSCIENCE
ALTSCHUL ET AL., J.MOL.BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., METH.ENZYM., vol. 266, 1996, pages 460 - 480
CHOTHIALESK, J.MOL.BIOL., vol. 196, 1987, pages 901 - 917
COLOMA, J.J. ET AL., BIOTECHNIQUES, vol. 11, 1991, pages 152 - 156
DAYHOFF: "Atlas of Protein Sequence and Structure 5", 1978, NATIONAL BIOMEDICAL RESEARCH FOUNDATION
HAMERS-CASTERMAN CATARHOUCH TMUYLDERMANS SROBINSON GHAMERS CSONGA EBBENDAHMAN NHAMERS R.: "Naturally occurring antibodies devoid of light chains", NATURE, vol. 363, 1993, pages 446 - 448, XP002535892, DOI: 10.1038/363446a0
J. SAMBROOK, MOLECULAR CLONING: A LABORATORY MANUAL
LARRICK, J.W. ET AL., SCAND. J. IMMUNOL., vol. 32, 1990, pages 121 - 128
METH.MOL.BIOL., vol. 70, 1997, pages 173 - 187
NEEDLEMAN ET AL., J.MOL.BIOL., vol. 48, 1970, pages 443
PEARSON ET AL., PROC.NATL.ACAD.SCI., vol. 85, 1988, pages 2444
See also references of EP4596581A4
SMITH ET AL., ADV. APPL. MATH., vol. 2, 1981, pages 4 82

Also Published As

Publication number Publication date
EP4596581A1 (en) 2025-08-06
IL320488A (en) 2025-06-01
US20250297012A1 (en) 2025-09-25
KR20250084976A (ko) 2025-06-11
AU2023370296A1 (en) 2025-05-15
CN115960234B (zh) 2023-12-29
JP2026512563A (ja) 2026-04-17
EP4596581A4 (en) 2026-02-18
ZA202503670B (en) 2025-12-17
CN115960234A (zh) 2023-04-14
MX2025004739A (es) 2025-06-02

Similar Documents

Publication Publication Date Title
US20250297012A1 (en) Anti-cd16a antibody and application thereof
US20260078186A1 (en) Anti-pdl1 antibody and use thereof
CN114907479B (zh) 抗cd112r抗体及其用途
WO2024087521A1 (zh) 抗cd3的抗体及其应用
US20260022178A1 (en) Anti-cd94 antibody and use thereof
CN118027195B (zh) 亲和力成熟的mica抗体及其应用
KR20250116776A (ko) 항cd155 항체 및 이의 적용
WO2023036215A1 (zh) 双特异性抗原结合分子及其应用
CN115960231A (zh) 抗cd138的抗体及其应用
JP2024522075A (ja) 抗ｃｅａ及び抗ｃｄ１３７多重特異性抗体ならびにそれらの使用方法
WO2025124055A1 (zh) 阻断性cd40抗体及其应用
CN117586402A (zh) NKp80抗体及其应用
CN117964772A (zh) NKp80-CD155双特异性抗体及其应用
EP4613767A1 (en) Bispecific antibody for glypican-3 and use thereof
CN116284397A (zh) 抗b7h6的抗体及其应用
US20240376196A1 (en) Cd112 antibody and use
CN116284406B (zh) 一种pd-1结合蛋白及其应用
WO2022068891A1 (zh) Pd-1抗体及其制备方法与应用
CN121005780A (zh) 靶向hla-g的抗体或其抗原结合片段及其应用
CN121930353A (zh) 双特异性抗体及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23881112

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 320488

Country of ref document: IL

Ref document number: MX/A/2025/004739

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2025524844

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025524844

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2023881112

Country of ref document: EP

Ref document number: AU2023370296

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2023881112

Country of ref document: EP

Effective date: 20250429

ENP Entry into the national phase

Ref document number: 2023370296

Country of ref document: AU

Date of ref document: 20230404

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20257017243

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020257017243

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2025112750

Country of ref document: RU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11202502803P

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: 11202502803P

Country of ref document: SG

WWP Wipo information: published in national office

Ref document number: MX/A/2025/004739

Country of ref document: MX

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112025008168

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: 1020257017243

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2025112750

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2023881112

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 112025008168

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20250425